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SUMMARY
This study describes:
I. The cloning of the CVP 19 gene and construction of the intracellular expression
vector pPIC3.5K-CYP19.
ii. The transformation of the yeast, Pichia pastoris with the constructed vector.
iii. The expression ofP450arom in Pichia pastoris.
iv. The determination of enzyme activity and isolation of the protein from the Pichia
pastoris cells.
v. The expression of P450c 17 in Pichia pastoris.
VI. The determination of kinetic constants for the conversion of progesterone to
170H-progesterone and 160H-progesterone by P450c17.
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OPSOMMING
Hierdie studie beskryf:
1. Die klonering van die CVP 19 geen en die konstruksie van die intrasellulêre
uitdrukkingsplasmied, pPIC3.5K-CYPI9.
Il. Die transformasie van die gis, Pichia pastoris, met die gekonstrueerde plasmied.
iii. Die uitdrukking van aromatase in Pichia pastoris.
IV. Die bepaling van ensiemaktiwiteit en die isolering van die proteïen vanuit Pichia
pastoris.
v. Die uitdrukking van P450c17 in Pichia pastoris.
VI. Die bepaling van kinetiese konstantes vir die omsetting van progesteroon na
170H-progesteroon en 160H-progesteroon deur P450c17.
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ouers
Met liefde opgedra aan
my man
&
It is by logic that we prove, but it is by intuition that we discover.
(Henri Poincaré)
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AOXI
Aoxlp
AR-I
AR-2
BMGY
17j3-hydroxy-~5-steroiddehydrogenase-isomerase
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CO Carbon monoxide
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COX2 Cyclooxygenase 2
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CRE cis-acting cAMP regulatory elements
CYP17 Cytochrome P450 17a.-hydroxylase gene
CYPl9 Cytochrome P450 19a.-hydroxylase gene
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Da
DHEA
El
E2
EC
Dalton
Dehydroepiandrosterone
Estrone
Estradiol
Endometrium cancer
EDTA Ethylenediaminetetra-acetic acid disodium salt
ELISA
ER
FAD
FMN
HPLC
IMAC
kb
kDa
MD
MM
NAD
NADPH
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Enzyme linked immunosorbent assay
Endoplasmic reticulum
Flavine adenine dinucleotide
Flavine mononucleotide
High Performance Liquid Chromatography
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Kilo bases
kilo Dalton
Minimal dextrose
Minimal methanol
Nicotinamide adenine dinucleotide
Nicotinamide adenine dinucleotide phosphate (reduced)
3-oxodecalin-4-ene-IO-carboxaldehyde
Product of the CYP19 gene
Product of the CYP I 7 gene
Product of the CYP21 gene
Polycystic ovarian syndrome
P450arom
P450c17
P450c21
PCOS
PCR Polymerase chain reaction
PMSF
RT-PCR
Phenyl methyl-sulfonyl fluoride
Reverse transcriptase polymerase chain reaction
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SDS Sodium dodecyl sulphate
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SNP
uv
YPD
Single nucleotide polymorphism
Ultra violet
Yeast extract peptone dextrose medium
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4CHAPTER ONE
1.1 Introduction
Cytochrome P450 enzymes are a family of heme-containing enzymes, defined by their
characteristic enzymatic function as monooxygenases [1,2]. They are so-called because
of the characteristic band displayed at 450nm, by the ferrous (Fe2+) carbon monoxide
complex in the proto porphyrin IX heme nucleus. Cytochromes P450 playa large role in
the detoxification of xenobiotics in the body (exogenous substrate metabolism). In
addition to this, the cytochrome P450 enzymes are also responsible for the metabolism of
steroids, vitamins, fatty acids and eicosanoids (endogenous substrate metabolism). These
enzymes are found in all five of the biological kingdoms, with the exception of certain
primitive species of bacteria [2,3]. Although the cytochromes P450 are present in most
tissues in mammalian species, they are predominantly found in the endoplasmic
reticulum (ER) membrane of hepatocytes in the liver. In addition to this major expression
site for cytochromes P450, there are also various other forms expressed in other tissues
and organs, such as the kidneys, brain, breast, nasal epithelium, prostate, gonads, skin,
spleen, lung, gastro-intestinal tract and pancreas [2,4]. For the conversion of cholesterol
to steroid hormones, a sequence of cytochrome P450-dependent monooxygenation
reactions, together with ~-5 to ~-4 isomerization coupled to NAD-dependent oxidation of
the 3~-hydroxyl function, is required. There are three microsomal cytochrome P450
enzymes that partake in steroidogenesis, namely P450c21 (21-hydroxylase), P450c17
(cytochrome P450 17a-hydroxylase/17 ,20-lyase) and aromatase (product of the CVP 19
gene), the latter two will form the focus of this study [2,5].
P450c 17 is expressed in the adrenals, ovaries and testis and catalyses two different
reactions. The first is the relative simple 17a-hydroxylation of pregnenolone and
progesterone to yield 17a-hydroxypregnenolone (l70Hpreg) and 17a-
hydroxyprogesterone (l70Hprog), respectively. The second reaction is a 17, 20
oxygenase-dependent cleavage, also known as a lyase reaction, to yield
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5dehydroepiandrosterone (DHEA) from 170Hpreg and adrostenedione from 170Hprog
[2,5,7].
Aromatase displays tissue-specific regulation and is expressed in the ovaries, placenta,
brain and adipose tissues. This enzyme catalyses three sequential oxygenation reactions
that convert C19 androgens to aromatic C18 estrogens. This three step oxidative process
includes both aromatase and the flavoprotein NADPH-cytochrome P450 reductase, and
requires three equivalents of molecular oxygen and NADPH per estrogen molecule
formed [2,6,8,9]. The increased incidence of both breast cancer and endometrial cancer
(EC) can be correlated to estrogen biosynthesis by adipose tissue that increases with body
weight and age [10]. Together, these two microsomal P450 enzymes, P450c17 and
aromatase, play an integral role in steroidogenesis, more specifically in the production of
sex steroids. Androgens are produced via DHEA, one of the products of the lyase activity
of P450c17. Androgens are converted by aromatase to estrogens. Reduced P450c17
activity or a non-functional enzyme leads to a decrease in sex steroids production in
males and can result in ambiguous genital formation, while in females, puberty may
never be reached. Breast cancer as well as EC is believed to develop and progress as a
result of abnormal expression of aromatase [11,12].
Chapter two of this thesis describes the structure, spectral properties and general catalytic
mechanisms of cytochrome P450-dependent enzymes. This chapter also reviews the role
of cytochromes P450 in steroidogenesis, the location of these enzymes and the electron
donor systems. In chapter three, aromatase is discussed in depth in terms of physical
properties, role in steroidogenesis, membrane topology, localization and its role in female
cancers.
For the expression of aromatase in the yeast Pichia pastoris, it was necessary to construct
an expression vector containing the CYP19 gene. The cloning of CYP 19 gene into
Escherichia coli and two different approaches to transform P. pastoris with the
constructed expression vector, are discussed in Chapter four. This Chapter also discusses
the expression of aromatase in P. pastoris as well as the characterization, isolation and
purification of the enzyme from isolated yeast microsomes. The results obtained from the
cloning, electroporation, expression and purification are also presented and discussed.
Stellenbosch University http://scholar.sun.ac.za
6In Chapter five, an overview is given of P450c 17 in terms of physical properties, zonal
distribution, membrane topology and its role in adrenal steroidogenesis and cancer.
Chapter six discusses the growth conditions of the P. pastoris cells, transformed with
P450c 17, as well as the kinetic studies that were conducted with this enzyme. This
Chapter also presents the results obtained from the work that was done on the P450c 17
enzyme, followed by a discussion. In the conclusion, a summary of the data obtained
from this study is given and presents an overview of the main points concluded from this
work.
Stellenbosch University http://scholar.sun.ac.za
7CHAPTER TWO
Cytochromes P450
2.1 Introduction
In 1955, G. R. Williams and M. Klingenberg independently noticed a pigment with an
atypical carbon monoxide-binding spectrum in rat liver mierosomes [1]. This pigment,
when reduced, had an absorption maximum at 450nm. Cytochrome b5 has an absorption
maximum at 420nm when reduced and was the only known hemoprotein in rat liver
mierosomes at that time. In 1962, Tsuneo Omura and Ryo Sato [1] published their
findings and proposed the name "P450" for this "new" hemoprotein, which means "a
pigment with an absorption at 450nm". When mierosomes were treated with a detergent
or a phospholipase preparation, the active cytochrome P450 was converted to cytochrome
P420 (P420), the inactive form of the enzyme. It was established that P420 also had
hemoprotein properties and this confirmed that the membrane bound cytochrome P450
should also be a hemoprotein [1,2]. A unique feature of cytochrome P450 hemoproteins
is a thiolate in the active centre, which is ligated to the iron atom of protoporphyrin IX
[13]. Since the discovery in liver microsomes, many other forms of cytochrome P450-
dependent enzymes have been found in both the ER and the mitochondria. These
enzymes are also called the monooxygenases and they activate molecular oxygen with
the resultant oxidation of the substrate. A single oxygen atom is incorporated into an
organic substrate to produce a molecule of water and a monooxygenated metabolite.
Many different reactions are catalysed by the cytochrome P450 monooxygenases, such as
the hydroxylation of carbons, the oxygenation of nitrogen, sulfur, halogens and
phosphorus as well as the epoxidation of double bonds. Substrates for cytochromes P450
are endogenous as well as exogenous and include fatty acids, lipids, vitamins, steroids,
carcinogens and xenobiotics [1-4,7,13].
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82.2 The general structure of cytochromesP450
The molecular mass of cytochromes P450 varies between 44 and 60 kilo Dalton (kDa), as
determined by SDS-gel electrophoresis [14-18]. The enzyme comprises a single
polypeptide chain and typically about 45 to 55 percent of the amino acid residues are
non-polar and the amino terminal residues are effectively free. As previously mentioned,
cytochromes P450 have an iron protoporphyrin IX as a prosthetic group and is part of the
b-type hemoproteins [2,14-18]. This prosthetic group is located in a large hydrophobic
cleft. The heme group is loosely bound by a combination of hydrophobic interactions,
Coulombic attractions and covalent bonds. A cysteine thiolate anion is the 5th axial ligand
of the hemoprotein. The presence of this s" ligand ensures the unique ability of the
enzyme to undergo autoxidation. The hydrophobic environment of the active site is
crucial to the ionization of the -SH group. If this environment is disturbed, the enzyme is
converted to its inactive form, cytochrome P420, as the thiolate anion cannot serve as the
5th ligand anymore. The 6th ligand is bound weakly to the heme group and dissociates
when iron reduction takes place or is easily replaced. This ligand is in a highly conserved
region of the protein and plays a key role in the formation of the oxygen binding site
where it acts as a binding site for molecular oxygen upon reduction of the heme group
[13,14,16,17]. Fig. 2.2.1 is a schematic representation of the active site of cytochrome
P450 enzymes. The S represents a sulfur ligand [21].
Fig. 2.2.1. Model of the active site of cytochrome P450-dependent enzymes.
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92.3 Spectralproperties
Upon replacement of the 6th ligand, the spin state of the Fe3+ in the protoporphyrin IX
prosthetic group of cytochrome P450 changes from a low spin, hexa-coordinated shape,
to a high spin, penta-coordinated shape as shown in Fig. 2.3.1.
X
N / N RH N N
/."FE~/ VIN"";'---' N N N
I FÊ"I
I IS S
/ /CYS CYS
(1) (2)
Fig. 2.3.1. Position of the low spin (1) and high spin Fe3+ in the ring [13).
During catalysis the 6th ligand is replaced by the substrate which leads to the uptake of
electrons, allowing for the binding of oxygen to the complex. When binding of the
substrate occurs the iron is displaced from the plane of the pyrole ring towards the
thiolate sulphur [13,19]. This change can be determined spectrophotometrically.
Important information about the active site, as well as the mode of action of cytochrome
P450 dependent enzymes, has been gleaned from their characteristic difference spectra
[4,13]. There are three different types of substrate binding, namely Type I, Type II and
reverse jype I, also known as modified Type II. These types relate to the heme iron spin-
state modulation together with ligation at the distal heme face. Type I is a shift in the spin
equilibrium towards high spin. The shift in the Soret band absorption maximum is at
420nm with an associated increase of the 390nm absorption in ferric cytochrome P450
UV spectrum. Type II binding refers to a decrease in UV absorption at 390 - 405nm with
an increase at - 425 - 435nm. This is a shift towards low spin ferric state. It indicates a
direct heme iron ligation by substrate cytochrome P450 inhibition. Reverse Type I or
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modified Type II is essentially a 'mirror image' of Type I. It is thought that iron heme
ligation does not occur in this instance [2,4,16].
2.4 General catalytic cycle of cytochromes P450
The cytochrome P450 catalytic cycle essentially involves the combination of oxygen with
the organic substrate (RH) to produce a molecule of water and a mono-oxygenated
metabolite (ROH). Most of the reactions begin with the transfer of electrons in two
consecutive steps once the substrate has bound. The first electron is transferred from
NAD(P)H to either NADPH-cytochrome P450 reductase in the microsomal system, or to
a ferredoxin reductase and a nonheme iron protein in the mitochondrial and bacterial
systems. The second electron is transferred to cytochrome P450 leading to the reductive
activation of molecular oxygen followed by the insertion of one oxygen atom into the
substrate to form a mono-oxygenated metabolite while the other oxygen atom is
incorporated in a molecule of water [4,16,20,21]. The general reaction equation of the
cytochrome P450 catalytic cycle can be written as follows:
RH + O2 + NAD(P)H + W _. ROH + H20 + NAD(Pt
Substrates, for the vast variety of cytochrome P450 enzymes are mostly lipophilic such as
the fatty acids, eicosanoids, steroids, lipid hydroperoxides and retinoids. Some of the
substrates are highly hydrophilic despite earlier beliefs that they were mostly
hydrophobic. Some other substrates for cytochromes P450 include the xenobiotics,
antioxidants, pesticides, herbicides, alcohols, solvents and other foreign substances. With
so many different substrates, it comes as no surprise that this unique group of enzymes is
capable of many different reactions including hydroxylation, peroxygenation,
dehalogenation, epoxidation, desulfuration as well as reduction and it is peculiar that,
more than forty years after they were first discovered, these enzyme are still collectively
known as the cytochromes P450. This name, first used to describe a red pigment with a
reduced CO difference spectrum at 450nm, seems unsuitable as it does not describe the
biological functions of the enzymes at all. Even the term cytochrome in the name is an
anomaly, since cytochrome P450-dependent enzymes do not act purely as electron
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carriers as cytochromes normally do. In the light of this controversy, it has been
suggested that the name should be changed to diversozymes [1-4,20,22]. Some of the
transformation reactions carried out by the cytochromes P450 is vital for life, e.g. the
conversion of cholesterol to the corticoid and sex hormones. Other reactions, like the
detoxification of xenobiotics lead to more polar compounds that can be more easily
excreted. The catalytic cycle of a typical cytochrome P450 catalysed reaction can be
summarized in four steps:
a. Substrate binding with displacement of the sixth ligand inducing a shift in the
absorbance maximum, spin state and redox potential of the hemoprotein system.
b. One-electron reduction of the complex to a ferrous state, driven by the increase in
redox potential that results from the previous step.
c. Binding of molecular oxygen to give a superoxide complex.
d. A second reduction step leading to an 'activated oxygen species'.
2.4.1 Stages in the catalytic cycle of cytochrome P450-dependent enzymes
Fig. 2.4.1 is a schematic representation of the catalytic cycle of cytochrome-dependent
P450 enzymes, while Table 2.4.1 summarizes the different spin states of the heme iron
[14].
2
Fe2+-RH
~o::--- I
O2
4
Fig. 2.4.1. Catalytic cycle of cytochrome P450-dependent enzymes. RH represents a substrate and
ROH the corresponding product. The heme iron redox state is also shown for each stage (3}.
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Table 2-1 d-Orbital electron arrangement of the heme iron with the cytochrome P450 substrate-free
and substrate-bound (14).
Coordination Ferric Iron Soret Band Substrate
Valence Spin State d Electrons (nm)
6 Low HHi 420 Absent
5 High iiiH 390 Bound
The first step in the reaction cycle of cytochrome P450 is substrate binding. Ferric
cytochrome P450 combines with the substrate to form an enzyme-substrate complex.
This disturbs the spin-state equilibrium and aids the uptake of the first electron. It is
believed that the main contributor to the binding energy is the hydrophobic effect.
Substrate binding causes the coordination sphere to change from hexacoordinated to
pentacoordinated, as mentioned earlier. This also results in changes in the d-orbitals and
the electron pairing pattern shifts from ferric low spin (S = ~) to ferric high spin (S =
5/2). The high spin iron moves out of the plane of the pyrole ring towards the thiolate
sulfur, the reason for this being that the high spin iron has a larger ionic radius and can no
longer fit in the central cavity of the porphyrin IX nucleus [4,16,21].
The second step in the catalytic cycle is the one-electron reduction of substrate-bound
cytochrome P450. This reducing equivalent can be provided by either NADH or
NADPH, depending on the type of system i.e. mitochondrial or microsomal electron
transport system. Once the redox partner provides an electron to the enzyme-substrate
complex, the ferric iron of the hemoprotein is reduced to the ferrous form while
remaining high spin. This switch from ferric to ferrous state, allows molecular oxygen to
bind strongly to cytochrome P450 through heme ligation [4,16,21,23].
Dioxygen binding is the third step in the catalytic cycle. It involves the interaction
between ferrous substrate-bound cytochrome P450 and dioxygen. This results in an
oxyferro complex of cytochrome P450 also known as oxycytochrome P450 and is in
effect the first step of oxygen activation [14,15,16,18].
In the 4th step of the cycle, the second electron transfer activates 02 to ol-. At the same
time an internal rearrangement of the electrons takes place to restore the iron to its ferric
(Fe3~ state. This step initiates dioxygen bond cleavage to yield the catalytically active
species [7,13,16,20].
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The s" step involves dioxygen bond cleavage, which consequently leads to one oxygen
atom being inserted into the substrate while the other oxygen atom is reduced to a water
molecule. After these steps are completed, the hydroxylated product can dissociate from
the cytochrome P450 enzyme active site. This completes the catalytic cycle and the free
oxidized form of the cytochrome P450 can again enter into the next cycle [4,16,21,24].
2.5 The electron donor systems
2.5.1 The mitochondrial electron transport system
Mitochondrial and most bacterial cytochrome P450-dependent systems consist of three
components: ferredoxin (an iron-sulfur protein), NAD(P)H-ferredoxin reductase and
cytochrome P450. Adrenodoxin (ADX) is an adrenal ferredoxin and is found in the
matrix and on the inner membrane of the mitochondria. ADX transfers electrons from
NAD(P)H-adrenodoxin reductase (ADXR) to the adrenal mitochondrial cytochromes
P450, P450scc (cytochrome P450 side chain cleavage) and P45011p. The ADX iron-sulfur
centre consists of two iron atoms that are tetrahedrally coordinated by four cysteine
residues and two sulfur atoms. Only a single electron can be introduced into the active
centre of oxidized ADX. ADXR is found on the matrix side of the inner mitochondrial
membrane and is highly specific for NADPH. It contains only one molecule of FAD. The
flow of electrons from the reduced pyridine nucleotide to cytochrome P450 can be
presented as follows:
NADPH ___. ADXR ___. ADX ___. P450
(FAD)
Studies by Lambeth et al. [25,26] provided the basic information that describes the
steroidogenic electron transport in adrenal mitochondria. NADPH donates an electron to
ADXR which in turn transfers it to the oxidized form of ADX. ADX first forms a
complex with NADPH-reduced ADXR from which it accepts an electron. ADX
dissociates from ADXR and acts as a one electron shuttle to reassociate with the
membrane bound cytochrome P450 to donate the electron to the hemoprotein. After the
electron has been donated to the hemoprotein, the reduced ADX is ready to receive
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another electron from ADXR [2,25,26,27]. Fig. 2.5.1 shows a schematic representation of
the mitochondrial electron transport system [27].
NADPH
NADP
Fig. 2.5.1. Schematic representation of the steroidogenic mitochondrial electron transport system
(261·
2.5.2 The microsomal electron transport system
The eukaryotic microsomal electron transport system consists of two components:
NADPH-cytochrome P450 reductase and cytochrome P450, which are both membrane
bound. There is not, as is the case in the mitochondria, an iron-sulfur protein that acts as
an electron shuttle. The flow of electrons from the reduced pyridine nucleotides to
cytochrome P450 in the microsomal transport system can be presented as follows:
NADPH ___. P450-reductase ___. P450
(FAD + FMN) ~ ./'
NADH ___. bs-reductase --. b5 ___. other enzymes
(FAD)
The NADPH-cytochrome P450 reductase contains one molecule of FMN and one
molecule of FAD. In the mitochondrial system, only one FAD molecule is found in
ADXR. Two reducing equivalents are supplied from NADPH by the NADPH-
cytochrome P450 reductase to cytochrome P450. Studies by Vermilion and Coon [28]
yielded vital information on the functioning of the microsomal electron transport system.
It was hypothesized that the FAD molecule is a low-potential flavin, which serves as an
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electron acceptor from NADPH. The high-potential flavin, FMN, acts as an electron
carrier in the transfer process from NADPH to cytochrome P450. FAD can accept two
reducing equivalents from NADPH, while FMN serves as the one electron shuttle
between NADPH and cytochrome P450 [2,27,28]. In liver mierosomes there are two
types of electron transport systems. The one system is as described above, while the other
system has NADH-cytochrome b5 reductase as a flavoprotein reductase. The NADH-
cytochrome b, reductase accepts two electrons from NADH and subsequently transfers it
to the one-electron acceptor cytochrome bs, in an electron transport pathway terminating
in either cytochrome P450 in the ER or fatty acyl CoA desaturase. NADH-cytochrome b5
reductase, a membrane-bound amphipathic flavoprotein contains one molecule of FAD
[29]. Fig. 2.5.2 is a schematic representation of the microsomal electron transport system
[27].
NADPH
NADP
Fig. 2.5.2. Schematic representation of the steroidogenic microsomal electron transport system (26).
2.6 The role of cytochromes P450 in steroidogenesis
Cholesterol is the precursor of all steroid hormones. These steroid hormones are
biosynthesized through a sequence of cytochrome P450-dependent monooxygenation
reactions. The steroidogenic cytochrome P450-dependent enzymes, responsible for
steroid biosynthesis, are found in the adrenal cortex, testis, ovary, placenta, brain and
adipose tissues. There are four major steroid hormones that differ from cholesterol in
their A and B rings, namely cortisol, aldosterone, androstenedione and estradiol. The
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differences in the rings of the first three hormones are brought about by a prominent
microsomal enzyme, 3~-hydroxysteroid-~5 -isomerase-dehydrogenase (3~HSD), and not
by the cytochromes P450. The first step in the biosynthesis of steroids, the conversion of
cholesterol to pregnenolone in the mitochondria, is catalysed by the cytochrome P450-
dependent cholesterol side chain cleavage enzyme, P450scc. The formation of
pregnenolone involves three successive reactions, i.e. two hydroxylase reactions at
positions 22 and 20 of cholesterol, which is followed by the cleavage of the vicinal diol
to pregnenolone and aldehyde. Pregnenolone moves from the mitochondria into the
mierosomes for the subsequent steps in steroidogenesis. The intermediates of adrenal
steroidogenesis must return to the mitochondria for either the production of aldosterone, a
mineralocorticoid in the zona glomerulosa, or the formation of glucocorticoids in the
zona fasciculata. During the microsomal steps, three cytochromes P450 are involved.
P450c 17 can catalyse either a 17a-hydroxylation of progesterone or pregnenolone or it
can catalyse a lyase reaction, which is the 17,20 oxygenase dependent cleavage of either
170Hpreg or 170H-prog to yield DHEA or androstenedione, respectively. Progesterone
or 170Hprog also undergoes a 21-hydroxylation reaction, which is catalysed by
P450c21, expressed only in the adrenal cortex. The third microsomal cytochrome P450
involved in steroidogenesis is aromatase. This enzyme, like P450scc, catalyzes three
sequential oxygenation reactions to convert C19 androgens to aromatic C 18 estrogens
[2,5,6,8,9,14,15,30]. Fig. 2.6.1 shows the steroid hormone biosynthesis pathway.
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Fig. 2.6.1. Major pathways in steroid hormone biosyndtesis
2.7 Summary
The cytochromes P450 are a large, diverse group of unique enzymes that not only
catalyse the conversion of endogenous substrates, but also exogenous substrates. These
reactions are vital for the sustained health and development of the organism in the
production of steroid hormones. Cytochrome P450-dependent reactions are also involved
in detoxification and toxic substances are converted to soluble, more readily excreted
products. All cytochrome P450-dependent enzymes have the same general structure, an
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iron protoporphyrin IX ring as prosthetic group that is located in a large hydrophobic
cleft on the surface of the cytochrome P450 protein. The 5th axial ligand of the
hemoprotein is a cysteine thiolate anion and this ligand is responsible for some of the
unique chemical and physical properties of this enzyme class.
".-
There are two major groups of cytochromes P450, depending on their location. These two
groups are the mitochondrial and microsomal cytochromes P450. The most unique
characteristics of these enzymes are their spectral properties. The substrate and specific
function of the cytochrome P450 can lead to slight changes in the general catalytic cycle
that is applicable to all cytochromes P450. The catalytic cycle can be summarized in four
steps: substrate binding, a single electron reduction of the substrate-enzyme complex,
binding of molecular oxygen and a second reduction step that leads to product formation.
The mitochondrial cytochromes P450 utilize ADXR (a flavoprotein with one molecule
FAD) and ADX (an iron-sulfur protein) to transfer electrons from NADPH to cytochrome
P450. The microsomal cytochromes P450 use only a flavoprotein, with both FAD and
FMN as an electron carrier.
During steroidogenesis, cholesterol is the precursor of all steroids and is converted to
pregnenolone by mitochondrial P450scc. P450c17 has a dual activity, either 17a-
hydroxylations or a 17, 20 oxygenase dependent reaction. P450c21 catalyses 21-
hydroxylation reactions in the mierosomes with either progesterone or 170Hprog as
substrates. The microsomal aromatase is responsible for the conversion of androgens to
aromatic estrogens.
It is clear that cytochromes P450 play an essential role in biological processes in humans
for maintaining the health and wellbeing of the individual. Mutations or malfunctioning
of genes encoding cytochromes P450 that are required for endogenous metabolism, may
give rise to human diseases such as female cancers, i.e. breast cancer, EC as well as some
male cancers. Aromatase and P450c 17 have been linked to these disease states and it
would thus prove useful to have a heterologous expression system for these proteins,
producing sufficient amounts of protein for further studies including kinetic assays,
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enzymology, immunohistochemistry and immunocytochemistry. Since there is such a
vast majority of cytochromes P450, we are still at the early stages of understanding their
many roles in human homeostasis. Therefore the challenge is to better define their role in
metabolism and to develop methods for determining their expression levels and activities
in vivo.
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CHAPTER THREE
Cytochrome P450arom
Cytochrome P450arom (P450arom), also referred to as aromatase, is the product of the
CYP 19 gene. CYP19 is part of the P450 superfamily of genes comprising over 300
members in about 36 gene families. Aromatase displays tissue-specific regulation and is
expressed in the male and female gonads, brain, placenta and adipose tissue among others
[2,6,8,9,31]. This enzyme is essential for the biosynthesis of estrogens from androgens
(Fig. 3.1) and is unique in that it catalyses three sequential hydroxylations to produce an
aromatic C18 estrogen. This entire reaction is known as aromatization since it involves
the conversion of the ~4-3-one A-ring of the androgens to the phenolic A-ring, distinctive
of estrogens [2,6,8,9,31].
Androstenedione 19-01 19-al Estrone
Fig. 3.1. Conversion of androgens to estrogens by aromatase [8].
3.1 The big question: Is aromatase a cytochrome P450?
In 1974, Thompson and Siiteri [32] posed the question whether a P450-dependent
enzyme can be responsible for the aromatization of adrostenedione. It was already known
that the placental aromatase was a microsomal enzyme. Thompson and Siiteri [32]
established that the addition of adrostenedione to placental microsomes, which contained
NADPH, led to an increase in the rate of NADPH and oxygen consumption associated
with estrogen production. Thorough inhibition studies with KCN led Thompson and
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Siiteri [32] to the conclusion that the production of one mole of estrogen required 3 moles
of oxygen and 3 moles ofNADPH. This stoichiometry suggested that aromatization was
brought about by three mixed function oxidation reactions, involving three sequential
hydroxylations [32]. Their data also showed that 19-oxoandrostenedione precedes the
formation of estrogen, suggesting that the second intermediate must be either the 19-
aldehyde or the 19-geminal diol. Subsequent experiments proved the latter [32]. The
stoichiometry of aromatization, as well as the nature of the first two hydroxylations that
were elucidated, suggested that a single species of cytochrome P450 catalyzed the mixed
function oxidations in the process of converting androgens to estrogens. By this time,
however, other researchers showed that the aromatization of adrostenedione was
insensitive to carbon monoxide (CO) [33,34]. It was believed by some that this evidence
was sufficient to prove that a cytochrome P450-dependent enzyme was not involved in
the aromatization of C 19 steroids [35]. Other reports, however, indicated that CO
insensitivity was not the only measure for the determination of cytochrome P450
involvement in this reaction [36]. This dispute encouraged Thompson and Siiteri [32,37]
to broaden their investigation into the likely involvement of cytochrome P450 in
aromatization as the CO inhibition studies were not sufficient to provide conclusive
evidence for the involvement of a cytochrome P450 in the aromatization of C19 steroids.
They used different approaches, such as spectrophotometric investigation of the binding
of various steroids to placental microsomes, immunochemical techniques and chemical
inhibitor studies to establish unambiguously if a cytochrome P450-dependent enzyme
was indeed involved in the formation of the sex steroid precursors [37].
The previous observations of the 3 O2 : 3 NADPH : 1 estrogen stoichiometry for the
aromatization of C19 steroids, and the presence of cytochrome P450 in human placental
mierosomes at the same concentrations found in other steroidogenic tissues, indicated
that cytochrome P450 was involved in aromatization [32]. Results from studies with
known cytochrome P450 inhibitors were also consistent with the involvement of a
cytochrome P450. Thompson and Siiteri [37] showed that there was competitive binding
to cytochrome P450 by androstenedione, 19-hydroxyandrostenedione and 19-
oxoandrostenedione. These results indicated that all the reactions involved in C19
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aromatization were catalysed at the same active site and suggested that a single enzyme
complex was responsible for the aromatization of both C18 and C19 steroids [37]. From
this ground-breaking work Thompson and Siiteri concluded that a single species of
cytochrome P450 was responsible for the aromatization of both C18 and C19 steroids
through three consecutive hydroxylations [37]. Their work showed that conclusions could
not be drawn on the participation of cytochrome P450 in a given reaction based on CO
inhibition studies alone [32,37]. The following mechanism was proposed for the
hydroxylations catalyzed by all microsomal cytochrome P450 (Fig. 3.1.1) [37].
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Fig. 3.1.1. Proposed mechanism (as suggested by Thompson and Siiteri) of all microsomal
cytochrome P450-catalyzed hydroxylations (37).
By 1985, it was still unclear if aromatase was a cytochrome P450-dependent enzyme and
if three sequential hydroxylations took place to produce an estrogen. In a critical and
comprehensive review of data available in 1985, Hall [15] again raised the problem that
the conversion of adrostenedione to estrone was not inhibited by CO. From the available
data Hall [15] proposed that the hydroxylation at C19 was followed by oxidation to a
ketone. This step could then be followed by the oxidative elimination of formic acid.
However, the reaction mechanism of step II remained unclear. Two possibilities were
proposed: the one being a second hydroxylation by monooxygenation whereby the
unstable 19-geminal diol would spontaneously collapse to the ketone. The second
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possibility was the dehydrogenation of the single hydroxyl group in 19-
hydroxyandrostenedione that would lead to the formation of 19-ketoandrostendione. Hall
[15] suggested that the use of enzymology and photochemistry would be the only
methods to prove the involvement of cytochrome P450 in any reaction beyond any doubt.
Since various research groups encountered problems with these methodologies, Hall [15]
concluded that it was still impossible to say with certainty that a single cytochrome P450
enzyme was involved in aromatization.
Corbin et al. [38] conducted studies on the full-length cDNA encoding human aromatase.
They derived the amino acid sequence of human aromatase from the open reading frame
and compared it with that of other forms of cytochrome P450. Corbin et al. [38] found
that the derived coding region of human aromatase indicated without a doubt that this
polypeptide belonged to a member of the cytochrome P450 super family of genes. The
sequence contains regions of marked homology to those of other members, particularly
an alleged membrane-spanning region, I-helix, Ozols and heme-binding regions. From
these results they concluded that cytochrome P450arom belongs, like other steroidogenic
P450 species, to a separate gene family within the super family. Corbin et al. [38] cloned
human aromatase cDNA and expressed the enzyme in COS 1monkey kidney tumor cells.
The deduced amino acid sequence was similar in size to human placental aromatase and
catalyzed the aromatization of androstenedione, testosterone and 16a-
hydroxyandrostenedione. During the experiments, they were also able to inhibit the
reaction with known aromatase inhibitors. The research group of Corbin et al. [38]
concluded that the aromatization reaction appeared to be catalyzed by a single
polypeptide encoded by the CYP19gene.
3.2 The CYP19 gene
The CYP 19 gene is located at chromosome 15q21.2 and consists of a 30 kilo bases (kb)
coding region and a 93 kb regulatory region. The coding region of this gene, encoding
human aromatase, spans nine exons commencing with exon II. Ten different tissue-
specific promoters are found in the large regulatory region and are alternatively used in
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different cell types. The common splice acceptor site seems to be the key mechanism
behind the recruitment of such a large number of promoters. The activation of each
promoter leads to splicing of an untranslated first exon onto this common junction
directly upstream of the translation start site in the coding region [31,39,40].
Mahendroo et al. [40] and Simpson et al. [31] investigated the unusual model of
alternative promoter usage in CYP 19. Although different promoters of the CVP 19 gene
regulate the expression of aromatase in different tissues, an identical aromatase enzyme is
expressed in all cells and tissue types [31,40]. The CYP19 gene is very large and differs
from other genes encoding cytochrome P450 enzymes in that many untranslated first
exons are found in aromatase transcripts in a tissue-specific fashion. This phenomenon
may be ascribed to tissue-specific promoters, which induce differential splicing. For
example, the ovaries synthesize mostly estradiol, while the placenta produces estriol.
Adipose tissue is responsible for synthesizing mainly estrone. The CI9 steroid presented
to the aromatase enzyme, in each tissue type, yields different tissue specific CI8 steroids
[31,40].
Aromatase expression in the granulosa cells of the ovary is controlled by the cAMP
mediated gonadotropin, FSH. The proximal promoter, promoter II, that is situated
directly upstream of exon II, is responsible for the expression of aromatase in the ovary
[31,40]. In adipose tissue, adipocytes and adipose stromal cells express aromatase.
Simpson et al. [31] found that aromatase expression and activity are much higher in the
stromal cells that surround adipocytes. Transcripts from this tissue contain a distal,
untranslated exon, 1.4, located about 20 kb downstream from exon 1.1, which means that
it is 15 kb upstream from the start of translation. Mahendroo et al. [40] concluded from
their results that a second transcript, with a different 5' terminus, is present in adipose
tissue. These transcripts contain exon 1.3 located 100 kb upstream of exon II. In contrast,
placental transcripts contain an untranslated exon 1.1 at their 5' -ends, located 40 kb
upstream from the start of translation in exon II. A minor population of transcripts in the
placenta contains exon 1.2 in the 5' -untranslated region. As mentioned earlier, splicing of
the untranslated exons occurs at a common 3' -splice junction upstream of the start of
translation, to give rise to the identical mature transcripts [40]. This indicates that human
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aromatase is encoded by a single-copy gene, regardless of the site of expression or the
fact that different transcripts contain different 5' -termini (Fig. 3.2.1) [31,40].
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Fig. 3.2.1. Tbe buman CYP19 gene. Tbe septum in tbe open bar in exon II represents tbe common 3'-
acceptor splice junction for tbe untranslated exons [31].
The physiological role of aromatase expression in adipose tissue still has not been fully
elucidated. Some functions of aromatase activity in this tissue may include the
maintenance of bone mineralization, thus preventing osteoporosis in both sexes, and the
development of female reproductive organs. Inappropriate activation of abnormal
promoters upregulates aromatase expression in estrogen dependent pathologic tissues
such as breast cancer and endometriosis. Simpson et al. [31] used RT-peR to examine
local variations in aromatase expression in breast adipose tissue. They found that the
highest expression of aromatase occurs in adipose tissue surrounding a tumor, as
compared to expression distal to a tumor [31]. Mahendroo et al. [40] predicted that
promoter 1.4 is present only in breast tissue and that the other promoter found in adipose
tissue, promoter 1.3, is present in upper and lower body fat. In normal breast adipose
tissue, aromatase expression is kept at low levels via promoter 1.4, 73 kb upstream of the
common coding region. In breast cancer, promoters II and 1.3 activities are increased, and
in addition the endothelial-type promoter 1.7 is also upregulated [40]. From the results of
Bulun et al. [39] it can be seen that, in estrogen-dependent malignancy breast cancer, four
promoters are used for the expression of aromatase (II, 1.3, 1.7 and 1.4) compared to
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normal breast adipose tissue which makes almost exclusive use of only promoter 1.4. The
observations of Simpson et al. [31] and Bulun et al. [39] established that there is a
definite form of communication between a breast tumor and the surrounding adipose cells
in terms of the ability of the adipose cells to produce estrogens.
3.3 The mechanism of aromatasecatalysis
As mentioned earlier, aromatase is a microsomal cytochrome P450-dependent enzyme
that converts androgens to estrogens via three sequential oxidations and researchers have
been able to isolate the 19-hydroxy and 19-oxo androgen intermediates formed in this
reaction. The isolation of these intermediates suggested that the first two oxidation
reactions occurred at the Cl9 carbon of the substrate. However, the mechanism of the CIO-
Cl9 bond cleavage or the third oxidation has, to date, not been established. Several
theories exist for the mechanism of the third oxidation. Korzekwa et al. [41], and others,
have proposed two viable general mechanisms for the third oxidation step. The first
proposal involves the addition of a peroxy intermediate to the aldehyde followed by
homolytic or heterolytic bond cleavage. The second mechanism includes various
intermediates involving the formation of a l-radical intermediate. Korzekwa et al. [41]
have used theoretical calculations to model reactions that involve the formation of 1-
radical intermediates. These reactions also included the direct addition of the hydroxyl
radical equivalent to the aldehyde group, followed by homolytic cleavage of the CIO-CI9
carbon bond. When the hydroxyl radical was added to the aldehyde by direct addition,
energy barriers of +IOkcal/mol were observed (Fig. 3.3.1). However, this hydroxy radical
is extremely reactive and is therefore unlikely to serve as a good model for the active
oxygenating species of a cytochrome P450-dependent enzyme. Very large energy barriers
were found for the addition reaction when more stable radicals were used. This data
suggested that the direct addition of the hydroxyl radical equivalent to the aldehyde is not
a likely mechanism for carbon bond cleavage [41]. The ability of the functional group to
stabilize the resultant radical correlates with the activation energies. The 2-ene-3-01 forms
of the l-radical appear to be favored over the keto forms. However, when there is
competition with recombination to form the 1p-hydroxyandrogen, CIO-CI9 cleavage from
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the enol would be favored. The enol radical is much more stable than the ketone and this
means a slower recombination rate. The A-ring of both the ketone and enol radical
intermediates is bent below the plane of the steroid, while the estrogen products' A-ring
is bent above the steroid plane. The geometries of the transition states for CIO-CI9
cleavage are similar to the androgen substrates. This means that binding energy is likely
to be lost during I-radical formation and regained in the transition state of the cleavage
reaction (Fig. 3.3.2) [41].
Fe
I.0.
Fig. 3.3.1. I-radical formation followed by direct addition of the hydroxyl radical equivalent to the
aldehyde (41).
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Fig. 3.3.2. Schematic representation of the Cj-radical formation followed by C.O-C.9 bond cleavage
(41).
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Korzekwa et al. [41] did not model the alternative reaction of peroxy addition, however,
other experimental evidence suggested that these peroxy intermediates are involved in
cytochrome P450 mediated deformylation reactions. There are three general known
mechanisms for the addition of a peroxy intermediate, one hemolytic and two heterolytic
(Fig. 3.3.3). In the homolytic mechanism a Ip-hydrogen atom is transferred. In one
heterolytic mechanism a proton is transferred while in the other a hydride is transferred
[41]. These three mechanisms are concerted mechanisms with the disadvantage that cis-
elimination of the IP-hydrogen and 19-carbon must occur. However, most elimination
reactions are transdiaxial [41]. These three transfer mechanisms involve the breaking and
forming of three different bonds, which may lead to different stepwise mechanisms.
Korzekwa et al. [41] considered the possibility of the generation of the diol in the active
site in order for deformylation to occur. However, gem-diols have a low hydrophobicity
and may therefore be poor substrates for cytochrome P450 implying that, if a diol is
generated in the active site of the cytochrome P450 enzyme, the hydrogen
abstraction/carbon-carbon cleavage reactions may take place as described earlier. From
their results they concluded that the exact mechanism of the third hydroxylation step of
aromatase was unclear [41]. No experimental evidence existed to indicate that the
cytochrome P450 mediated deformylation reactions occur by hydrogen atom abstraction
followed by carbon-carbon bond cleavage. The research group of Korzekwa et al. [41]
suggested that more experimental data on u- and P-substituent effects would shed light on
the true mechanism.
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Fig. 3.3.3. Concerted mechanisms for the conversion of a peroxy addition intermediate to the
deformylated product. A and C show the heterolytic mechanisms, where a proton and a hydride are
transferred, respectively. B shows the homolytic mechanism where a Ill-hydrogen atom is
transferred (41).
Akhtar et al. [42] were also studying the mechanistic properties of aromatase at the same
time as Korzekwa et al. [41]. The conversion of androgens to estrogens is marked by
replacing various methyl groups with hydrogen atoms. The removal of a methyl group is
energetically unfavorable and thus unlikely. It is therefore more likely that the methyl
group is oxidized to a carboxylic acid derivative where after it is removed as C02. Akhtar
et al. [42] proposed that the carbon-carbon bond cleavage reaction is made possible by
the involvement of the FeIII-O-OH species, trapped by the electrophilic property of the
carbonyl compound. This complex gives rise to a peroxide adduct producing an acyl-
carbon cleavage by fragmentation (Fig. 3.3.4). Akhtar et al. [42] concluded from their
results that aromatase shows catalytic pluralism, which is dependent on the electronic
structure of the substrate. When a binary complex is formed from a substrate containing a
C-H or C=C bond that is fittingly orientated, the hydroperoxide undergoes an oxygen-
oxygen cleavage to yield the oxo-derivative. This derivative participates in further
reactions. Alternatively, when the binary complex involves a carbonyl containing
substrate, the FeIII-O-OH species is intercepted by the electrophilic property of this group,
providing the peroxide adduct that then fragments (3 in Fig. 3.3.5). According to Akhtar
et al. [42], aromatase makes use of this acyl-carbon cleavage pathway. Aromatase must
have evolved an active-site architecture that ensures a slow conversion of FeIII-O-OH to
Stellenbosch University http://scholar.sun.ac.za
30
FeIV -0· for the bimolecular process, 1 - 3 in Fig. 3.3.5, to compete with it, permitting
peroxide adduct formation [42]. Fig. 3.3.5 is a schematic representation of the proposal of
Akhtar et al. [42] suggesting that the carbon-carbon bond cleavage reaction is made
possible by the involvement of the FeIII-O-OH species that is trapped by the electrophilic
property of the carbonyl compound. Fig. 3.3.4 shows the acyl-carbon cleavage [42].
CHO
+ HCOOH
Fig. 3.3.4. Acyl-carbon bond cleavage mechanism (42).
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Fig. 3.3.5. Schematic representation of the carbon-carbon bond cleavage reaction, made possible by
the involvement of the Felll-O-OH species that is trapped by the electrophilic property of the
carbonyl compound (42J.
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The research group of Kao et al. [8] investigated the mechanism of aromatase using site-
directed mutagenesis. As reported previously, the first two aromatase reactions are
hydroxylations at position C 19 of androgens. The oxygen activation of the third step
leads to steroid ring A aromatization. The exact mechanism of the aromatization reaction
remains to be confirmed. Kao et al. [8] proposed that a better understanding of the
structure-function relationship of aromatase would provide the molecular basis for the
reaction mechanism. The same laboratory also investigated the reaction mechanism by
using five aromatase mutants to verify and refine their computer model. The prepared
mutants were evaluated by inhibitory profile studies, enzyme kinetic analysis and
reaction intermediate measurements. Glu302, Ser478 and His480 were indicated to
potentially play an important role in catalysis and are likely to be closer to the active site
than what was previously believed. Glu302 in the I-helix is considered an essential part
of the active site of aromatase [8]. The results obtained by Kao et al. [8] suggested that
the acidic group at this exact position is necessary for aromatase activity. A computer
model showed that Glu302 is located near the C19 position of the substrate. As a result of
this positioning, it was proposed that this residue is responsible for splitting the oxygen-
oxygen bond which leads to the oxygen activation by forming an iron-oxo intermediate in
the first hydroxylation step. Mutations of His480 to Lys led to higher activity than
His480 to GIn, while having similar Km values for androstenedione as the wild-type
enzyme. This suggests that a positively charged amino acid is required at this position.
However, these mutations result in lower estrone levels, which may mean that His480
plays an important part in aromatization and not so much in the first two hydroxylations.
With His480 located close to C-3 and C-4 of the steroid, it may form a hydrogen bond
with the C-3 keto group of the substrate and participate in the aromatization. His480 and
Asp309 are two residues involved in the enolization at the 3-keto group of the 19-
aldehyde androgen. The third step in the aromatase mechanism is suggested to be a
peroxidative attack. Graham-Lorence and Peterson [43] and Kao et al. [8] suggested that
the aromatization of the A ring follows the concerted mechanism as proposed by Coon et
al [22].
For studies of the reaction where the 1O~-methyl group of the androgen nucleus is
removed by aromatase, Coon et al. [22] synthesized 3-oxodecalin-4-ene-l0-
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carboxaldehyde (ODEC) as an analog of the A and B rings of the 1O~-formylandrogen
intermediate. They found that this analog undergoes aromatization to yield 3-hydroxy-
6,7,8,9-tetrahydronaphthalene (Fig. 3.3.6).
OHC
.. + HCOOH
Fig. 3.3.6. Conversion ofODEC to hydroxytetrahydronaphthalene as catalyzed by P450 2B4 (22).
The conversion of this compound is similar to the steroid decarbonylation reaction in two
ways. The deuterium in the formyl group of ODEC was preserved in the product, formic
acid. The desaturation reaction was specific for the removal of the I~-hydrogen atom.
This shows that it is a stereospecific cis elimination of formate. Coon et al. [22] proposed
the following concerted mechanism for the aldehyde deformylation (3rd step in aromatase
mechanism) (Fig. 3.3.7) with 2-methylbutyraldehyde as a substrate. With NADPH
present, an oxygen deprived cytochrome P450 heme iron-bound hydroperoxide reacts
with the electrophilic carbonyl group of the 19-aldehyde forming an enzyme-bound
peroxyhemiacetal-like intermediate. The double bond between C I and CI 0 and formic
acid would then be produced with rearrangement via a concerted mechanism, while
alcohol, the alkane as well as formic acid can be produced by a stepwise mechanism with
the help of a transient carbon radical [8,22].
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Fig. 3.3.7. Proposed concerted mechanism for the aldehyde deformylation as catalysed by aromatase,
among other P450 enzymes. 2-methylbutyraldehyde was used as substrate [221.
The studies conducted by Kao et al. [8] and Coon et al. [22] have shed some light on the
third aromatization step of aromatase. Computer-modeling, site-directed mutagenesis,
inhibitor binding studies and intermediate profile analysis have played important roles in
understanding the mechanism, however, more work must be done to completely unlock
the mystery surrounding the third step of the aromatase reaction mechanism [8,22].
It is important to fully understand the catalytic mechanism of aromatase, since aromatase
malfunction has been implicated in many diseases, especially breast cancer. If the
mechanism is understood, the development of effective aromatase inhibitors will be
facilitated.
3.4 Aromatase and breast cancer
Many women, especially in industrialized countries, suffer from breast cancer and other
related cancers. With 1 million new cases of breast cancer diagnosed each year, it is an
important risk factor that contributes to the morbidity and mortality of women around the
world. Estrogens play an important physiological role in the human body. It is involved
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in the development and maintenance of the female sexual organs, the reproductive cycle,
reproduction, various neuroendocrine functions as well as the preservation of bone
density. The normal mammary gland is directly affected by estrogen to promote growth
and differentiation [44-46].
The release of pituitary prolactin is stimulated by estrogen. Prolactin acts on the
mammary cell, supporting both normal mammary gland and tumor growth in the absence
of ovaries and adrenals. Since estrogen cannot support mammary tumor growth in the
absence of pituitary prolactin, some consider estrogen as probably being essential but not
sufficient for the growth of certain tumors in breast tissue. Breast cancer is often hormone
responsive, which means that the tumor contains estrogen receptors and requires estrogen
for growth. In primary tumors, the values of estrogen receptors range from zero to 1000
fmol/mg of cytosol protein [48]. In 1974 an extensive study was performed to validate
the suggestion made by Jensen and DeSombre [47] that the presence of estrogen
receptors in malignant breast tissue might indicate that the tumor is hormone dependent.
This observation may lead to the appropriate endocrine treatment with regression of the
tumor. The results that McGuire et al. [48] obtained from their studies can be
summarized as follows: Estrogen receptor values can be extremely useful in predicting
results obtained with endocrine therapy. Patients, who had negative tumor estrogen
receptor values, did not readily respond to endocrine therapy. A high percentage of
patients with positive estrogen receptor values, responded favorably to endocrine
treatment [48].
Estrogen has also been linked to the development of endometrial cancer. This disease
usually occurs in women long after menopause is characterized by the elevated levels of
estrogen production in nonendoerine tissues. A number of studies indicated that both
estrogen and progesterone receptors were increased by estrogen administration in uterine
tissues [49]. Since estrogen as well as progesterone levels fluctuate immensely during the
menstrual cycle, progesterone must also be considered as a contributing factor to breast
cancer. Huggins et al. [50-52] suggested that progesterone plays a role in stimulating
tumor growth. The mechanism is, however unclear as it can either directly affect the
tumor or modify the actions of other steroid hormones. It is possible that estrogen and
progesterone exert feedback control on each other in the target tissue. Even after
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considering progesterone, this steroid is still only apart of the complex hormonal control
system that affects the growth and function of mammary cells. McGuire et al. [48] found
that there are receptors present in MCF-7 cells for progestins, androgens, glucocorticoids
and estrogens. Therefore, there is a complex interrelationship between various hormones
that mayor may not playa role in tumor growth; however, only estrogen, the product of
aromatase, will be discussed further in detail.
3.4.1 Estrogens and cancer risk
All estrogens have three major distinguishable features namely an aromatic A ring, a
phenolic hydroxyl group at the C-3 position and a methyl group at position C-13.
Estradiol has a hydroxyl group at C-17, whereas estrone has a keto-group in the same
position [11]. Fig. 3.4.1 is a schematic representation of the biosynthesis of estradiol from
cholesterol with all the enzymes involved. Aromatase is responsible for the conversion of
androstenedione to estrone as well as the production of estradiol from testosterone [12].
One third of all breast cancer patients have hormone-dependent breast cancer indicating
that the tumor contains estrogen receptors and requires estrogen for further growth.
Indeed, the case that one of the major known risk factors for breast cancer is associated
with the extended exposure to elevated levels of estrogen [12,45,46,53-56]. Aromatase
activity has been detected by many researchers in breast adipose tissue and breast cancer,
implicating estrogens in the development of breast carcinomas [12,45,46,53-56].
Estrogens have also been implicated in other estrogen-dependent neoplasms such as
endometriod, endometrial and surface epithelial-stromal ovarian carcinomas. The
intratumoral aromatase possibly plays a role in converting any circulating androgens to
estrogens, possibly with the aid of 17~-hydroxysteroid dehydrogenase (17~HSD) type 1
and estrogen sulfatase. This conversion may be an important mechanism of autocrine
stimulation in these hormone-dependent tumors [12,45,46,53-56]. There are many other
factors associated with the risk of cancer. Some of these risk factors include family
history and genetic factors, mammographic density, endogenous and exogenous
estrogens, bone density, age, diet and alcohol consumption [12,44,54,57].
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These risk factors are briefly listed below [12,44,54,57]:
Family history and genetic factors: BRCA1 was the first breast cancer susceptibility
gene that was identified and has been linked to ovarian and breast cancer [12,44,54,57].
Mammoeraphic density: A high percentage density in post-menopausal women put
them at a four times greater risk of developing breast cancer than women with a lower
percentage density [12,44,54,57].
Endogenous and exogenous estrozens: One of the first observations that suggested a
hormonal role for estrogens in breast cancer, was bilateral oophorectomy. The earlier in
life this procedure is carried out, the greater the risk reduction. It is also known that
women with high bone density are at greatest risk of developing breast cancer. Since
estrogens from any source is known to help retain bone mass, it is a possible to link bone
density and breast cancer [12,44,54,57].
Aee: Estrogen production increases as a function of aging and obesity. Another
observation was that the younger the age at menarche and the older the age at menopause,
the greater the risk of developing breast cancer. This observation suggests a direct
relation between the period a woman is exposed to cycling ovarian hormones
[12,44,54,57] .
Diet: Some researchers have found a correlation between high fat intake and breast
cancer risk, while others suggest diet only plays a role in children [12,44,54,57].
Alcohol consumption: Many groups have found a direct relation between an increased
breast cancer risk and the consumption of more than three alcoholic beverages per day
[12,44,54,57].
Although it is evident that there are many risk factors involved in breast cancer, however,
estrogens seem to be a major complex contributor to the risk of developing breast,
endometrial or ovarian cancer. Many research groups found a direct link between both
the level and presence of aromatase activity and tumor cellularity [46,53,58]. These
results suggest that cancer cells are the primary site of aromatase activity and that
aromatase, and thus estrogens, contribute to the synthesis of a tumor, especially in post-
menopausal women where ovaries are no longer the main source of estrogen production.
In post-menopausal women, estrogens are produced in extra glandular tissues. These
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estrogens may enter the bloodstream and subsequently on tumors via endocrine
mechanisms [46,53,58]. Aromatase activity and expression, and hence the production of
estrone is, however, the highest at the site of the malignant tumor or in areas proximal to
the tumor. It has been found that aromatase activity is predominantly the highest in
stromal cells. Tumors are made up of a large proportion of stromal cells that are close to
the tumor epithelial cells. If the growth of hormonally responsive breast tumors is indeed
stimulated by the in situ production of estrogen, paracrine interactions are required
between the stromal and the epithelial compartments. Santner et al. [58] have shown that
the stromal compartment contains most of the estrogen synthetic machinery, while the
epithelial cells contain the estrogen receptors. Stromal aromatase may be the most
important contributor to estrogen production in breast tumors, but the influence of other
enzymatic sources, cannot be ruled out [45,46,55,58].
Estrone, formed by aromatase in peripheral tissues, is only weakly estrogenic and must
be converted by 17~HSD to estradiol, the most potent estrogen, to exert its effects.
17~HSD has been detected in breast tumors together with estrone sulfotransferase, which
converts estrone to estrone sulfate [54,55,58]. Brueggemeier et al. [45] found a linear
correlation between the expression of aromatase and cyclooxygenases (COX-l and COX-
2) in breast cancer specimens. In breast cancer, both these enzymes are regulated by
complex paracrine interactions, resulting in significant consequences on the pathogenesis
of breast cancer [45,54,55,58].
Miller [46] found that estrogen receptors also play an important role in breast tumors.
However, estrogen biosynthesis can be detected in both estrogen receptor-positive and
negative cancers, but is more likely to be of significance in estrogen receptor-positive
tumors. Miller [46] postulated two possible explanations why increased levels of
aromatase are found in the adipose tissue of breast cancer patients. Firstly, it is possible
that the high activity of aromatase leads to elevated levels of estrogen, which promotes
cancerous growth at that specific site. The second reason might be that the malignant
tumors are secreting factors into the local environment that can either be responsible for
the induction or the stimulation of aromatase activity. Therefore, it is likely that the
cancerous tumor might induce the activity of aromatase in adjacent breast adipose tissue
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where higher levels of estrogen receptor-a is also detected. Estrogen receptor-a is thought
to mediate cellular proliferation.
Esteban et al. [53] have found it difficult to relate the functional significance to locally
produced estrogens in the absence of estrogen-receptors, since no correlation was seen
between intratumoral estrogen production, aromatase activity, as well as estrogen and
progesterone receptors. It is possible that estrogen binds to different receptors than those
detected by their experimental methods [44,46,53]. Another receptor, estrogen receptor-B.
has also been identified in various estrogen target tissues as well as normal and malignant
breast tissue. However, this receptor has different binding affinities and tissue
distribution compared to estrogen receptor-a. Estrogen receptor-a levels increase and
decrease with the menstrual cycle, while the levels of estrogen receptor-B remain
constant, and are high from birth to adulthood. Maintaining a constant level may regulate
the proliferation of cells negatively, which in turn may have a protective role in normal
breast tissue. Estrogen is responsible for down-regulating estrogen receptor-a levels and
some breast cancers might be a result of the inability of estrogen to fulfill this regulatory
role. During breast as well as ovarian carcinogenesis, estrogen receptor-a is over
expressed at much higher levels than estrogen receptor-B, which seems to be down
regulated [12,44,56,59,60]. Maggiolini et al. [56] suggested that the ratio of estrogen
receptor-o/B, together with determination and detection of intratumoral aromatase, may
be a solution to monitoring the potential responsiveness of hormone-dependent cancers.
The question whether or not only estrogens will initiate breast cancer remains
controversial. Proliferation of normal and malignant breast cells take place when these
cells are exposed to estrogens. In the case of the malignant cells, the proliferation of the
cells explains why estrogens increase breast cancer risk. A high rate of cellular
proliferation in normal cells may lead to the accumulation of DNA adducts and
ultimately mutations, since the cells have less time to repair DNA damage. Hilakivi-
Clarke et al. [44] thus proposed that estrogens may initiate breast cancer only once the
DNA repair mechanisms are damaged. Mitrunen et al. [12] reported that rapid cell
proliferation lead to a greater chance of genetic error. Only once mutations have been
introduced into the cell, can estrogens enhance the replication of the cells carrying these
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mutations. Estrogens induce free-radical-mediated DNA damage, some of these damages
include single-strand DNA nicks, an increase in 8-hydroxyguanine formation, estrogen-
DNA adducts, lipid peroxidation and protein oxidation. Thus, many researchers suggest
that the DNA repair enzymes may influence the risk of cancer [12,44].
Other factors may also influence the occurrence of breast cancer. Maggiolini et al. [56]
identified several transcriptional enhancers secreted from breast carcinomas, which
control aromatase expression in the malignant tissue. They also found that the
overexpression of aromatase is associated with different coding start sites or alternative
splicing events in exon I.Maggiolini et al. [56] concluded that aromatase inhibitors could
prove to be an adjuvant therapeutic strategy for the treatment of hormone dependent
breast tumors, especially in post-menopausal women.
3.4.2 Gene expression, promoter usage and polymorphisms in cancer
As mentioned before, Bulun et al. [39] reported that, in estrogen-dependent malignancy
breast cancer, four promoters are used for the expression of aromatase (II, 1.3, 1.7 and
1.4). In normal breast adipose tissue promoter 1.4 is used almost exclusively.
Brueggemeier et al. [45] also observed that, when aromatase expression levels are
elevated in breast cancer tissues, a switch occurs in the major promoter region utilized
with promoter II, specific for the ovary, testis and prostate, being used predominantly.
When Utsumi et al. [61] investigated the relationship between aromatase mRNA levels
and the alternative use of multiple exons 1 in human breast tissue, they reported that
when this switch of promoter 1.4 to 1.3 occurs, it leads to increased levels of aromatase
mRNA in some patients. The mRNA that is transcribed from promoter 1.3 in breast
cancer exhibits a higher incidence of involved nodes than those transcribed from
promoter 1.4 [61]. The regulation of estrogen biosynthesis is normally controlled by
glucocorticoids and cytokines. However, when a promoter switch is observed, the control
changes to the cAMP-mediated pathway. Intracellular cAMP levels are increased by the
prostaglandin PGE2 and leads to stimulation of estrogen biosynthesis. Increased COX-l
and COX-2 gene expression results in enhanced COX enzyme levels. The elevated
enzyme levels lead to an increased production of prostaglandins, ultimately stimulating
aromatase expression and activity [45].
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There is paracrine interaction between stromal adipose cells and carcinoma cells and this
interaction might cause a change in the aromatase mRNA levels in breast cancer.
Inductive or suppressive factors, which are possibly secreted by carcinoma or
nonmalignant cells, may account for the difference of aromatase mRNA expression
levels. These factors can regulate the expression levels through interaction with the
promoter region of the CYP19 gene. Studies by Utsumi et al. [61] could not clarify
whether the increased levels of aromatase mRNA observed in cancerous tissue are a
consequence or cause of carcinogenesis. During carcinogenesis, the surrounding breast
stromal cells are under severe physiological conditions which may cause the promoter
switch of the human CYP 19 gene and hence the abnormal expression thereof [61].
Haiman et al. [62] examined the relationship between breast cancer risk and genetic
polymorphisms in the CYP19 gene. Previous research showed that there is a greater
frequency of tetranucleotide (TTTA)n repeat alleles in intron 4 among women affected
with cancer. No association between C to T single nucleotide polymorphism (SNP) in
exon 10 of CYPI9 and breast cancer risk was, however, observed. Haiman et al. [62]
were also unable to prove that the association between breast cancer risk and rare
tetranucleotide repeat alleles was accounted for by this SNP in exon 10. Unlike Haiman
et al. [62], Berstein et al. [63] reported that there was a significant association between
the level of aromatase mRNA and the presence of this SNP in exon lOin breast tumors.
They focused on the initiation and promotion of endometrial cancer and the influence of
estrogen on these processes [63]. In women with endometrial cancer, the A21A2 CYPI7
genotype is under-represented while CYP19 genotypes with the longest A6 and A7
alleles are over-represented [63]. These results indicated that higher aromatase activity is
detected in females with the highest risk of endometrial cancer. Women at high risk are
usually carriers of the Al/Al and Al/A2 CYP17 genotypes and A61A6 or A61A7 CYP19
genotypes. Normal human endometrium tissue does not express aromatase and it is only
detected in endometrium cancer tissue [63]. The results obtained by Bernstein et al. [63]
suggested that a 'high risk' CYP19 or CYP17 genotype transforms into a 'high activity'
phenotype of the tumor. This increases local estrogen production resulting in further
tumor growth. In depth analysis of intratumoral aromatase in tumors is therefore
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important to gain a better understanding of development and biological behavior of
tumors and the clinical management of patients [53,55,56].
3.5 Summary
The CYP19 gene is located at chromosome 15q21.2 and consists of a 30 kb coding region
and a 93 kb regulatory region. The product of this gene is known as the enzyme
aromatase. This enzyme is essential for the biosynthesis of estrogens from androgens and
it is unique in that it catalyses three sequential hydroxylations to produce an aromatic
C18 estrogen. The first two reactions are hydroxylations that take place on position C 19
of androgens that serve as substrates for aromatase. The oxygen activation in the third
step leads to aromatization of the steroid A-ring. All three these reactions are carried out
at the same active site of the single aromatase enzyme complex. There are ten different
tissue-specific promoters in the large regulatory region of the CYP 19 gene and they are
alternatively used in different cell types.
Aromatase activity has been detected by many researchers in breast cancer, implicating
that estrogens play a role in the development of breast carcinomas. Estrogens play an
important physiological role in the human body. All estrogens have three major
distinguishable features namely an aromatic A ring, a phenolic hydroxyl group at the C-3
position and a methyl group at position C-13. Estradiol has a hydroxyl group at C-17,
whereas estrone has a keto-group at the same position.
In estrogen-dependent malignancy breast cancer, four promoters are used for the
expression of aromatase (II, 1.3, 1.7 and 1.4). In normal breast adipose tissue almost only
promoter 1.4 is used. Many researchers have reported that when a switch of promoter 1.4
to 1.3occurs, it leads to increased levels of aromatase mRNA levels in some patients.
While stromal aromatase may be the most important contributor to estrogen production in
breast tumors, the influence that other enzymatic sources might have, has also been
investigated. Many research groups suggest that DNA repair enzymes playa major role
in the risk of cancer. When DNA repair enzymes are not functioning as well as they
should, mutations can easily be overseen during cell proliferation.
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Human cytochromes P450 only occur in low concentrations in tissues, making them
extremely difficult to study. However, when these proteins are heterologously expressed,
it becomes easier to determine the enzyme activities in a foreign environment, e.g. yeast,
as well as determining the structure/function relationships associated with cytochromes
P450 by site-directed mutagenesis. Expression of human cytochromes P450 in
heterologous expression systems could also aid in the evaluation ofxenobiotics' effect on
these enzymes and provide sufficient pure cytochrome P450 proteins for antibody
production, enabling the localization of aromatase in breast tissue, for example.
Human aromatase has been successfully expressed in COS I monkey kidney tumor cells
[38], in mammalian cells such as breast cancer cells (MCF-7) [64], in insect cells using a
baculovirus mediated system [9,65,66], in E. coli [10,67] and the protogynous wrasse,
Halichoeres tenuispinis [68]. In this study, we have successfully expressed the human
aromatase enzyme in the yeast P. pastoris. Much research still needs to be done on the
levels, mechanism of action and activity of aromatase in breast cancer. An economic and
effective method for the production of high yields of aromatase will therefore be essential
for further immunological and enzymological studies on this extremely important and
fascinating protein.
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CHAPTER FOUR
The expression of human CYP 19 in P. pastoris
4.1 Introduction
The mRNA encoding human aromatase has been localized in peripheral tissues in
previous studies [55,70]. Aromatase protein levels in these tissues have to date, not been
determined and there is still much controversy over the exact localization of this protein
in breast tissue (stroma vs. epithelia) [69,70]. Breast, endometrium and ovarian cancers
contribute significantly to female mortality rates worldwide [11,39,40,45-48,53,58] and
aromatase activity, catalysing the production of estrogens from androgens, has been
proved to be linked to the above-mentioned cancers [11,39,40,45-48,53,58]. In hormone-
dependent cancers, a continuous supply of estrogen is necessary for the initiation and
promotion of the tumor. The human CYP19 gene is tissue-specific and under the control
of alternative promoters by the means of alternative splicing mechanisms [11,39,40,45-
48,53,58].
The aim of this study was to express the human CYP19 gene in P. pastoris at high yields
to raise an antibody against for immunohistochemical studies that could ultimately lead to
the determination and localization of aromatase in normal and cancerous breast tissue via
enzyme linked immunosorbent assay (ELISA) and immunocytochemistry.
P. pastoris is a eukaryotic methylotrophic yeast, capable of metabolizing methanol as its
sole energy and carbon source. This expression system provides all the advantages of
higher eukaryotic expression, such as protein processing and folding as well as
posttranslational modification. The oxidation of methanol to formaldehyde is catalysed
by the enzyme alcohol oxidase (Aoxlp), utilizing molecular oxygen. This reaction
generates hydrogen peroxide that is very toxic to the cell. To avoid cell death, methanol
metabolism takes place in the peroxisomes [72-75]. The pPIC3.5K vector is a plasmid
designed to identify multiple integrations of a gene in the P. pastoris genome in vivo.
This 9004 bp plasmid provides intracellular expression of the gene of interest. It has five
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pastoris [74]. Fig. 4.1.1 is a schematic representation of the pPIC3.5K vector.
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4.2 Cloning ofCYP19 into the pPIC3.5K expression vector
4.2.1 Materials and methods
Unless otherwise specified, all reagents were purchased from Sigma and Merck. The
pGEM-T vector, containing the human CYP19 gene and the pPIC3.5K vector, was
located in E. coli strain JMI09 (Promega) cells. The CYP 19 gene, coding for six N-
terminal histidine residues, was previously cloned into the pGEM- T vector in our
laboratory to yield pGEM-T-CYPI9. Sterile Luria-Bertani (LB) medium (1 % tryptone,
0.5 % yeast extract, 1 % NaCl, pH 7.0 adjusted with NaOH) was used for the routine
growth in E. coli. Selection of bacteria transformants was carried out on LB-agar (15
gIL), containing ampicillin (100 ug/ml),
4.2.2 Isolation of pGEM- T-CYP19 and pPIC3.5K
Cultures of E. coli (100 ml), containing pGEM-T-CYPI9 and pPIC3.5K, were grown
overnight in LB medium at 3TC while shaking at 175 rpm (Innova shaking incubator,
New Brunswick). The plasmids were isolated with the Nucleobond® PC 100 plasmid
preparation (Macherey-Nagel) kit, according to manufacturer's specifications.
4.2.3 Purification of pPIC3.5K and CYP19 cDNA
4.2.3.1 Restriction digestion
pGEM-T-CYPI9 (1 ug x 12) and pPIC3.5K (l ug x 12) were restriction digested, for 120
min at 3TC, each in a final volume of 25 III containing 2.5 III SuRE/Cut Buffer H
(supplied) and Notl (1 U), (Roche). DNA loading buffer (0.1% Orange G (w/v), 20%
Ficoll (w/v), 10mM EDTA, pH 7) was added to the restriction digested pGEM-T-CYPI9
vector. The DNA fragments were separated by electrophoresis (55 V) on a low-melting
agarose gel (1%), in TAE buffer (40 mM Tris-acetate, 2 mM Na2EDTA.2H20 and 20
mM acetic acid), for 3 h at 4°C. Gels were stained with ethidium bromide (0.5 ug/ml) for
20 min. The stained DNA fragments were visualized on a UV transilluminator. The
CYP19 DNA band was excised and purified with the gel extraction kit (Qiagen Inc.),
according to manufacturer's specifications. The digested pPIC3.5K vector was purified
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with the Wizard™ DNA clean-up kit (promega), according to the manufacturer's
specifications.
4.2.3.2 Dephosphorylation
The linearised pPIC3.5K vector was dephosphorylated prior to ligation to prevent
religation of the vector in downstream reactions. The dephosphorylation mixture (30 ul)
containing DNA (6 ug), 3 ul reaction buffer (50 mM Tris-HCI, pH 9.3, 1 mM MgCh, 0.1
mM ZnCb and 1 mM spermidine) and calf intestinal alkaline phosphatase (ClAP) (2.03
U) (Promega) was incubated at 37°C for 30 min. An additional 2.03 U ClAP was added
and the reaction mixture incubated for 30 min. EDTA (2 ul, 0.5 M) was added and the
resultant reaction mixture incubated at 65°C for 20 min to terminate the
dephosphorylation reaction. The DNA was purified with the Magic DNA Clean-Up® kit
(Promega), according to the manufacturer's specifications.
4.2.3.3 Ligation
The purified CYP19 cDNA was subsequently ligated using 1:1, 1:3 and 1:5 molar ratios
of vector: insert DNA. DNA insert (200 ng) and vector (200 ng) was used for the 1:1
ratio in aIO ul ligation reaction containing T4 DNA ligase (l U) (Roche), 3 ul ligation
buffer (supplied) and ATP (20 nM). The reaction mixture was incubated at 4°C,
overnight.
4.2.4 Transformation of E.coli strain JMI09 cells with pPIC3.5K-CVP19
E. coli strain JMI09 (200 ml) was grown overnight in LB media, shaking at 175 rpm, at
3TC. Competent cells were prepared as described in the calcium chloride procedure by
Sambrook et al. [76]. The competent cells were transformed with the construct and
grown on LB-plates supplemented with ampicillin (100 ug/rnl). Positive transformants
were selected and grown overnight in LB media (5 ml) supplemented with ampicillin,
and the plasmids were purified with the Wizard™ Plus SV mini preparation kit
(Promega), according to manufacturer's instructions. A pPIC3.5K-CYPI9 positive clone
was inoculated in LB media (100 ml), as described previously. The pPIC3.5K-CYPI9
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construct was isolated using the Rapid midi preparation kit (Life Technologies),
according to manufacturer's specifications. The nucleotide sequence of CYPI9 gene
fragment in pPIC3.5K-CYPI9 was verified (University of Stellenbosch DNA sequencing
facility) using specific primers, two in the forward direction and three in the reverse
direction. The upstream primers were 5' AOX 1Pand AromB 1 and the downstream
primers were 3' AOX 1, AromA2 and AromB2. Table 4.1 represents the sequences of the
primers used for the DNA sequencing of the CYPI9 fragment.
Table 4.1. Table showing the sense and antisense primers' sequences used.
Primer Sequence
5'AOXIP 5' -GACTGGTTCCAA TTGACAAGC-3'
AromBi 5' -GTCACAGTCTGTGCTGAATC-3'
3'AOXI 5' - GCAAATGGCA TTCTGACATCC-3'
AromA2 5' -CTCCAACCTGTCCAGATGTG-3'
AromB2 5' -GCACTGGTTCACA TTCTCTC-3'
The plasmid was also subjected to polymerase chain reaction (PCR) to amplify the gene
using the 5'AOX primer and the 3'AOX primer. Each PCR amplification mixture (50 Ill)
contained pPIC3.5K-CYP19 DNA (400 ng), 200 11Meach of dATP, dTTP, dCTP and
dGTP, 2.5 11M each of the 5'AOX and 3'AOX primers and Super-therm DNA
Polymerase (2.5 U, Abgene). The following procedure was carried out in a PCR Sprint
(Hybaid): (1) denaturation at 94°C for 2 min; (2) 35 cycles of denaturing at 94°C for 1
min, annealing at 55"C for 1 min, and extension at noc for 1 min; and (3) a final
extension at noc for 7 min. DNA loading buffer (Sul), was added to 10111of each PCR
product mixture prior to electrophoresis. The PCR product was analyzed by agarose gel
electrophoresis as described in section 4.2.3.1.
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4.3 Transformation and homologous recombination in GS115 strains of P. pastoris
4.3.1 Introduction
Uptake of DNA is hindered by the yeast cell wall. It is therefore necessary to either
partially remove the cell wall, or to create pores to facilitate DNA uptake during
transformation. The transformation of P. pastoris cells with foreign DNA is less efficient
than that of Saccharomyces. Nevertheless, electroporation and spheroplasting provide the
highest efficiency of transformation (up to 103 to 104 transformants per ug DNA). For
this reason, both techniques were used in this study to determine which method provided
the highest copy number of the CYP19 gene integrated into the P. pastoris genome.
4.3.2 Materials and methods
P. pastoris strain GS115 (his4) (Invitrogen), used for the expression of human
cytochrome aromatase, were grown, transformed and analysed according to the
manufacturer's instructions. Yeast extract peptone dextrose (YPO) media (1 % yeast
extract, 2 % peptone, 2 % glucose) was used in the routine growth of yeast. Selection of
yeast transformants was carried out on minimal dextrose (MD) plates and contained: 13.4
g yeast nitrogen base without amino acids, 400 ug biotin, 20 g dextrose and 15 g agar per
liter. Minimal methanol (MM) plates contained 13.4 g yeast nitrogen base without amino
acids, 400 ug biotin, 5 ml methanol and 15 g agar per liter. Regeneration dextrose base
(ROB) plates contained 1 M sorbitol, 2 % dextrose, 1.34 % yeast nitrogen base without
amino acids, 4 x 10-5 % biotin, L-glutamic acid, L-methionine, L-Iysine, L-Ieucine, L-
isoleucine each at 0.005 % and 2 % agar. For heterologous expression P. pastoris was
grown in buffered minimal glycerol (BMGY) medium (0.1 M potassium phosphate pH
6.0, 1.34 % w/v yeast nitrogen base without amino acids, 4 x 10-5 % biotin, 1 % v/v
glycerol) or in buffered minimal methanol medium without glycerol, containing 0.5 %
v/v methanol (BMMY).
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4.3.2.1 Spheroplasting
P. pastoris GS 115 cells were grown and prepared for spheroplasting as described by the
manufacturer [74]. Plasmid DNA (201lg) was linearized with SacI (Promega). P. pastoris
GS115 (his4) was transformed by the spheroplasting method as previously described
[74]. The integration of the CYP19 gene into the P. pastoris genome was monitored as
described in section 4.3.2.3.
4.3.2.2 Electroporation
Plasmid DNA (151lg) was linearized with SacI. P. pastor is GS 115 (his4) was
transformed by electroporation (Bio-Rad GenePulser) as previously described [74]. After
transformation the integrity of yeast cells was monitored as described in section 4.3.2.3
below.
4.3.2.3 Verification of integrity of yeast cells after transformation
Transformed yeast cells were incubated on minimal dextrose RDB-agar plates (histidine
deficient plates). The plates were incubated for 4 days at 30°C to select for His+
recombinants. Yeast colonies were transferred to YPD-agar (histidine deficient) plates
containing G418 (Sigma) added at 0.25 and 0.50 mg/ml. The level of G418 resistance
correlates with the number of kanamycin resitance genes integrated into the P. pastoris
genome. A single copy of pPIC3.5K plasmid integrated imparts resistance to G418 at
0.25 mg/ml. Colonies were selected and transferred to either dextrose (MD) or methanol
(MM) minimal medium as a carbon source to determine the methanol utilization
phenotype of the cells. Transformants that displayed the ability to grow on both carbon
sources were selected for further evaluation and small-scale expression studies. The
presence of cDNA encoding aromatase integrated into the yeast genome was confirmed
by direct PCR analysis (PCR Sprint, Hybaid) applying sense and antisense
oligonucleotides to amplify the CYP19 gene. This protocol was adapted from a method as
described by Linder et al. [77]. Colonies were selected from MD plates, suspended in
sterile water (30 Ill) and lyticase (100 U) (crude, from Artrobacter luteus; Sigma) was
added and incubated for 15 min at 30°C. The digested cells were frozen in liquid nitrogen
(1 min) and the lysate was used for PCR amplification. Each PCR amplification mixture
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(50 JlI) contained DNA/cell lysate (5 JlI), 200 JlM each ofdATP, dGTP, dTTP and dCTP,
5'AOXI and 3'AOXI primers, each at 2.5 JlM and Super-therm DNA Polymerase (2.5
U) (Abgene ) in reaction buffer containing MgCh (25mM). The amplified DNA fragment
was analysed by agarose gel electrophoresis as described in section 4.2.3.1.
Single colonies containing the verified recombinants in P. pas/oris GS lIS were grown in
MD (larnl) overnight at 30°C, shaking at 275 rpm. Cells were isolated by centrifugation
at 3000 x g for 5 min at room temperature and resuspended in fresh, sterile MD
containing IS % glycerol. Cells were frozen in liquid nitrogen and stored at -80°C.
4.3.2.4 Expression of aromatase in P. pastoris
Several clones of the recombinant strains of P. pas/oris were screened for adequate
expression levels of the CYPI9 gene. P. pas/oris strains GSI15/pPIC3.5K-CYPI9 and
GSI15/pPIC3.5K were and incubated on YPD medium at 30°C until single colonies
appeared. Single colonies were collected from the different strains and grown for 18 h in
BMGY (25 ml), shaking at 275 rpm at 30°C, until the cultures reached an optical density
between 2 and 6 at 600 nm (OD6oo). The cells were harvested by centrifugation at
3500 x g for 5 min at room temperature. The cell pellet of each clone was resuspended to
an approximate OD6ooof I in BMMY (200 ml), covered with sterile gauze and incubation
was continued at 30°C with shaking at 275 rpm. Methanol was added after every 24 h to a
final concentration of 0.5% (v/v). Aliquots (1 ml) of the culture media were removed at
selected time intervals i.e. 0, 24, 48, and 60 h to determine the optimal time for
expression. Cells were harvested by centrifugation at 3500 x g and the resultant pellets
were stored at -80°C. The fractions were analysed for the presence of intracellular
heterologous aromatase proteins by SDS-PAGE (Coomassie staining) and immunoblot
analysis.
4.3.2.5 Screening for intracellular expression of aromatase
The cell pellets were thawed on ice and resuspended in 100 JlI Breaking Buffer (BB, 50
mM NaH2P04, pH 7.4, 1 mM PMSF, ImM EDTA and 5 % glycerol). All subsequent
steps were carried out at 4°C. The suspension was transferred to a 1.5 ml microcentrifuge
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tube and centrifuged at 3000 x g at 4°C for 10min. The washed cells were resuspended in
BB (50 Ill) and an equal volume (cells and buffer) of acid-washed glass beads (0.5 mm)
was added to each sample. The samples were vortexed for 30 s and placed on ice for 30 s
for 8 cycles. After completion of the cycles, the samples were subsequently centrifuged at
maximum speed in a bench top microcentrifuge for 10 min at 4°C. The clear lysate was
collected and stored at -20°C.
4.3.2.6 Analysis by SDS-PAGE and Western blot verification
SDS-P AGE was carried out according to the method of Laemmli [78] using an
acrylamide concentration of 10 % (v/v). Rainbow colored protein molecular weight
markers (Amersham Pharmacia) consisting of myosin (220 kDa), phosphorylase b (97.4
kDa), bovine serum albumin (66.2 kDa), ovalbumin (45 kDa), carbonic anhydrase (30
kDa), trypsin inhibitor (21 kDa) and lysozyme (14.4 kDa) were used. A semi-dry blotting
system was used for the electroblotting to transfer proteins from the SDS-PAGE gel onto
a nitrocellulose membrane (Schleicher and Schuele). The probe, a nickel activated
horseradish-peroxidase probe (INDIATMHisProbe-HRP, Pierce, Rockford, USA) diluted
1:3000 in TBST buffer, was visualized by chemiluminescence. The positive control used
was a six histidine tagged ureate oxidase (Pierce, Rockford, USA).
4.3.3 Development of an HPLC based aromatase assay in P. pastoris
P. pastoris strains GSl15/pPIC3.5K-CYP19 and GSl15/pPIC3.5K (control) were grown
as described in section 4.3.2.4 and androstenedione metabolism was investigated. The
parent vector strain (GSl15/pPIC3.5K) was included to serve as a control. Actively
growing yeast cells (5 x 107 cells/ml) were induced with methanol for 48 h in a total
volume of 200 ml in a shaking incubator at 30°C. After 48 h induction, the cell
suspension (4 ml per reaction) was harvested by centrifugation at 2000 x g for 5 min at
room temperature. The cell pellets were washed with phosphate buffered saline (PBS)
and resuspended in fresh BMMY (1 ml) induction media. The cell suspension was pre-
incubated for 15 min at 30°C in an Erlenmeyer flask (25 ml), whereafter the reaction was
initiated by adding an equal volume of androstenedione (10 IlM) in BMMY media (1 ml).
Stellenbosch University http://scholar.sun.ac.za
53
The conversion reaction was assayed for 2 h by taking samples (50 Ill) at 0, 10, 20, 30, 60
and 120 min. Steroids in the media were extracted with methylene chloride (100: 1
solvent to incubation mixture). The water phase was aspirated and the remaining
methylene chloride was evaporated under a stream of nitrogen gas. The dried steroids
were redissolved in a mixture of ethanol:methanol:diisopropyl ether (12.5:12.5:75) (140
Ill) for HPLC analyses. HPLC analyses was carried out on a Waters HPLC, equipped
with a model 590 solvent delivery system (Waters, Milford, MA), a Waters M490 UV
detector (Waters, Milford, MA), a Waters U6K injector (Waters, Milford, MA) and a
silica column (2 micron pore size, 15 cm in length, with an internal diameter of 3.9 mm,
Waters, Milford, MA). Solvents used for the separation of the steroids were filtered
through a 0.45 11m pore size membrane (Millipore) and degassed by sonication.
Androstenedione and estrone were injected as standards to determine the elution time of
the steroids on the silica column. The separation of the steroids was developed with an
isoeratic solvent mixture of ethanol:methanol:diisopropyl ether (12.5:12.5:75) over a 10
min period at a flow rate of I ml/min. Data were collected by the Delta Chromatography
Data system (version 5.0, DataWorX Pty. Ltd.) and integration of the resulting
chromatograms was done with CHROMuLAN software/.
4.3.4 Purification of the aromatase protein
4.3.4.1 Preparation of yeast cells for protein purification
Recombinant P. pastoris strains GSI15/pPIC3.5K-CYPI9 (200 ml) and
GSI15/pPIC3.5K (200 ml) were grown as described in section 4.3.2.4. After optimal
expression was reached, cultures were transferred to sterile Falcon tubes (50 ml) and
centrifuged in a bench top centrifuge at 2000 x g for 10 min at room temperature. The
cell pellets were resuspended in buffer Al (5 ml, 50 mM sodium phosphate, 1 mM
PMSF, 20 % glycerol (v/v), pH 7.6) per 5 g wet weight /5 ml and centrifuged at 2000 x g
for 10 min at 4°C. Buffer A2 (cell lysis buffer, 1 ml, 50 mM sodium phosphate, 1 mM
PMSF, 20 % glycerol (v/v), 1 mM EDTA, 10 mM ~-mercaptoethanol, pH 7.6) per 0.5 g
wet weight was added to all tubes. An equal volume of acid washed glass beads were
2 http://www.chromulan.org
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added and cells were disrupted by vortexing (lO x 30 s) at 4°C with intermediate cooling
on ice. The disrupted cells were transferred to centrifuge tubes (50 ml) and centrifuged at
14000 x g for 30 min at 4°C. From the lysate (crude extract) 100 III was collected for
analysis with SDS-PAGE. Emulgen 913 was added drop wise to a final concentration of
1% (v/v) while stirring the crude extract at 4°C. This step was carried out for 4 h,
whereafter 100 III of the yeast mierosomes were collected for later analysis. The
mierosomes were filtered through (0.45 11m, Millipore) and 100 III of the resulting
soluble membrane fraction was collected. The sample was purified on a HIS-Select™
cartridge (Sigma) by immobilized metal affinity chromatography (lMAcl
4.3.4.2 lMAC purification of aromatase
lMAC was carried out on a AKTAprime system equipped with an internal UV detector
and absorption was monitored at 280 nm. All buffers used for the purification of
aromatase were filtered (0.45Ilm, Millipore). The column was equilibrated with binding
buffer A (50 mM sodium phosphate, pH 8, 300 mM NaCI, 20 % glycerol (v/v), 0.1 %
Emulgen 913 (v/v), 5 mM imidazole). The crude soluble fraction (20 ml) was applied
manually onto the column. The His-tagged proteins were eluted with elution buffer B (20
mM sodium phosphate, 0.5 M NaCl, 250 mM imidazole, pH 7.4) at a flow rate of 1
ml/min. Fractions (l ml) were collected with a fraction collector and the data collected
with the PrimeView (Amersham Biosciences) software. A peak was observed once the
percentage concentration of elution buffer Breached 65 %. The fractions corresponding
to the elution time of the peak were concentrated (UItrafree - 4 centrifugal filter and tube,
Millipore) to 50111and prepared for SDS-PAGE and Western blot analyses as described
in section 4.3.2.6. Samples (l00 1lI), collected during the preparation of the cells (see
section 4.3.4.1), prior to IMAC purification were also included in these analyses as
controls.
3 Kolar, N.W. Department of Biochemistry, University of Stellenbosch, Stellenbosch Personal
correspondence
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4.4 Results
4.4.1 Transformation of E.coli JMI09 cells - Verification of integrity
After the isolation ofpGEM-T-CYPI9 and pPIC3.5K plasmids, both were digested with
Notl, The CVP 19 gene was gel-purified after electrophoresis of the digested fragments.
The digested plasmid was phosphorilated to minimize religation of the sticky ends. After
ligation of CYPI9 into pPIC3.5K and transformation of E. coli JMI09 cells with the
resultant construct (pPIC3.5K-CYPI9), the plasmid was isolated from the transformants.
The construct was subjected to DNA sequencing. PCR was carried out with both the
sense (5'AOXI) and antisense (3'AOX1) primers. Two DNA bands were present in the
PCR product of the construct (Fig. 4.4.1, lane 1). The larger fragment (-2200 bp)
corresponded to the amplified AOXI gene of the pPIC3.5K plasmid, while the smaller
fragment (-1771 bp) corresponded to the amplified CYP19 gene, which included the
flanking 5' PAOXI, and 3' AOXI regions.
bp 1 2 3 4 5
1584
21227
5148
4268
3530
-2200
-1771
Fig. 4.4.1. Analysis of PCR amplification of pPIC3.5K-CYP19. Amplified products (20 JlI) were
electrophoresed on a 1 % agarose gel, stained with EtBr and visualised on a UV transilluminator.
Two clear fragments were visible, the larger fragment corresponding to the amplified AOXI gene of
the pPIC3.5K plasmid and the smaller fragment corresponded to the amplified CYPI9 gene
including the flanking 5'PAOXI and 3'AOXI regions. Lane I: pPIC3.5K-CYP19 amplified with both a
sense and antisense primer. Lane 2: I..-marker digested with both EcoRI and HINDIII (Promega). Lane 3:
Positive control (pPIC3.5K). Lane 4: I..-marker digested with HINDlII (Promega). Lane 5: Negative
control (no DNA).
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4.4.2 Transformation of P. pastoris with CYP19 and verification of integrity into P.
pastoris GS115
Spheroplasting did not provide high transformation efficiency. Electroporation was more
efficient for the transformation of P. pastoris, hence this method was the method of
choice for all subsequent transformations.
PCR amplification followed by 1 % agarose gel electrophoretic analysis of lysed His+
transformants showed that the CYP19 was integrated correctly into the P. pastoris
genome. Two bands were visible after electrophoresis. The larger fragment (-2200 bp)
corresponded to the amplified AOXI gene of the pPIC3.5K plasmid, while the smaller
fragment (-1771 bp) corresponded to the amplified CYP 19 gene with the flanking 5'
PAOXI and 3' AOXI regions (Fig. 4.4.2, lane 4). P. pastoris cells with only the parent
vector pPIC3.5K present produced two PCR products - 492 bp and 2100 bp (Fig. 4.4.2,
lane 2).
bp
2 3 4 5 6 7
21227
5148
4268
3530
-2200
-1771
1584
492
Fig. 4.4.2. Analysis of the integration of CYPI9 into the yeast genome. P. pastoris clones were
subjected to direct PCR screening and amplified products (20 ul) were electrophoresed on a 1 %
agarose gel, stained with EtBr and visualised on a UV transilluminator. Two clear fragments were
visible, the larger fragment corresponding to the amplified AOXI gene of the pPIC3.5K plasmid and
the smaller fragment corresponded to the amplified CYPI9 gene including the flanking 5'PAOXI
and 3'AOXI regions. Lane I: GSI15/pPIC3.5K-CYP17. Lane 2: GS115/pPIC3.5K with no insert. Lane
3: A-marker digested with EcoRl and HindIII. Lane 4: GSl15/pPIC3.5K-CYPI9 amplification resulting in
2 bands (2200 and 1771 bp). Lane 5: A-marker digested with HindIII (Promega). Lane 6: Positive control
containing CYP19 fragment (1771 bp) amplified from pPIC3.5K-CYPI9. Lane 7: Negative control, PCR
amplification without DNA.
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4.4.3 Expression of aromatase inP. pastoris
After the successful transformation of P. pastoris, GS1l5/pPIC3.5K-CYPI9 cells were
induced to express human aromatase as described in section 4.3.2.4. A time course study
was done with the induced cells over a period of3 days to determine the optimum time of
expression. The optimum expression time was 48 h. Fig. 4.4.3 (A) illustrates the Western
blot analysis of the expression of human aromatase induced by methanol over a period of
time. The Western blot analysis, illustrated in Fig. 4.4.3 (8), represents different positive
clones of GS1l5/pPIC3.5K-CYPI9 at different expression times after induction by
methanol. Human His-aromatase in Western blot analysis was detected with a His-tag
probe directed against histidine-rich proteins at a dilution of 1:3000. Carbonic anhydrase
of the Rainbow marker is also detected with the His-tag probe, since it is a histidine-rich
protein.
A B
leD 123 4 5 6 7 8 91 2 3 4 5 6 7 8 9 10
220
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14.3
Fig. 4.4.3. (A) Westem blot analysis of total intracellular yeast proteins of GS1l5 cells induced to
express aromatase for 3 days Lane 1 and 2: GS 115 cells transformed with pPIC3.5K vector at 0 and 72 11,
respectively. Lane 3: Rainbow marker. Lanes 4-10: GS115 cells transformed with pPIC3.5K-CYF19
vector at 0, 6, 12,24,36,48 and 60 h, respectively. Detection was carried out using an INDIA HisProbe-
HRP at 1:3000. (B) Westem blot analysis of total intracellular proteins of specific clones of GS115
ceDs induced to express aromatase for 2.S days. Lane 1: Parent vector, 0 h; Lane 2~CYF 17,48 h;Lane
3: CYFI9, Clone 2, 48h; Lane 4: CYF19 Clone 15,48 h; Lane 5: Positive control; Lane 6: Rainbow
marker; Lane 7: Negative control; Lane 8: CYFI9 Clone 1,60 h; Lane 9: CYFI7, 60 h. Detection was
carried out using an INDIA HisProbe-HRP at a 1:3000 dilution. The arrow indicates aromatase at ± 55 leD.
Fractions were loaded on a maxÏ-SDS-PAGE gel (lO %) and subjected to Western blot
analyses to obtain better separation of the proteins and to further confirm the expression
of aromatase. Fig. 4.4.4 (A) is the stained SDS-PAGE gel of the total intracellular yeast
leD
220
97.4
66
30
21.5
14.3
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proteins of P. pastoris GS115 cells induced to express aromatase. GSI15/pPIC3.5K-
CYP17 was included as a positive control. The Western blot analysis (Fig. 4.4.4 (B)) was
carried out as previously described.
A
123456789
B
1 2 3 4 5 6 7 8 9 kD
220
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66
30
21.5
14.3
Fi~ 4.4.4. Analysis of total GSl15 intracellular pruteins at 48 h after induction to express arumatase.
(A) Image of SDS-PAGE (100/0)and (B) Western blot analysis using a His-tagged probe at 1:3000.
Lane I: CYP19 clone I,Oh; Lane2: CYFI9 clone 1,24 h; Lanel: CYFI9 clone Z, 24 h; Lane4: CYP19
clone 1,48 h; Lane 5: Rainbow marker; Lane 6: CYPI9 clone 2, 48 h; Lane 7: CYP17, 48 h; Lane 8:
Parent vector, 48 h. Lane 9: Negative control.
4.4.4 Conversion of androstenedione to estrone by aromatase
Since a His-tag probe directed at histidine-rich proteins was used for the identification of
aromatase, it was not possible to assume from the Western blot analyses alone that
human aromatase was being expressed in the yeast cells. A conversion assay was
therefore carried out to confirm that aromatase was indeed being expressed as an active
enzyme in the yeast cells. Human arornatase activity was determined in the yeast cells, by
assaying the conversion of androstenedione (10 J.1M) to estrone. An HPLC based
aromatase assay was developed for the detection and separation of androstenedione and
estrone. The separation was developed isocratically over 10 mm with
ethanol:methanol:diisopropyl ether (12.5:12.5:75) as solvent. Fig. 4.4.5 (I) shows the
separation of the standards, androstenedione (2 mg/ml) and estrone (4 mg/ml) while Fig.
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4.4.5 (II) represents a typical separation of the steroids obtained from the expression of
human aromatase in P. pas/oris after a 2 h assaying period.
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Fig. 4.4.5. (I) Elution profile of the standards for the conversion of androstenedione to estrone.
Estrone (A) elutes at 6.63 min and androstenedione (B) at 7.11 min. and (II) Elution profile of the
conversion of androstenedione (B) to estrone (A) by the transformed yeast cells after 2 h of assaying.
Samples were collected, in duplicate, at specific time intervals and the conversion assay
was repeated four times. Data was collected by a Delta Chromatography Data System
version 5.0 (DataWorX Pty.Ltd.) and analysed using CHROMuLAN 4. Fig. 4.4.6
summarizes the aromatase conversion in terms of substrate (androstenedione) depletion
and the product (estrone) formation. After 2 h, approximately 30 % of the
androstenedione was converted to estrone. Also included in the figure is the conversion
result of the yeast cells transformed with the vector with no insert. The rate of
androstenedione conversion by aromatase in the yeast cells was significantly lower than
the rate of progesterone conversion by yeast cells transformed with human CYP17, which
showed a conversion of approximately 80 % progesterone after 1 h (see section 6.3.1).
4 http://www.chromulan.org
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Fig. 4.4.6. Conversion of androstenedione to estrone by the human aromatase enzyme inP.pastoris.
After 2 h,30 % of the substrate is converted to product.
4.4.5 Purification of the expressed aromatase protein
Once the P. pastoris cells were expressed and analysed for aromatase expression the
protein was isolated and subsequently purified by !MAC.
Fig. 4.4.7 shows the elution profile of the His-tagged aromatase during IMAC
purification. Four fractions, corresponding to the visible peak, were super-concentrated to
50 ul and prepared for SDS-PAGE (Coomassie staining) and Western blot analysis (Fig.
4.4.8).
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Fig. 4.4.7. Elution profile of the purified His-tagged protein. The dark line represents the UV
absorbance. The protein eluted at 65 % buffer B.
The purified aromatase samples were electrophoresed on aIO % denaturing
polyacrylamide gel and visualized after staining (Fig. 4.4.8 (A)). Identical samples were
electrophoresed and transferred to a nitrocellulose membrane for Western Blot analysis
(Fig. 4.4.8 (B)). The samples that were collected during the preparation of yeast
mierosomes for the isolation of the aromatase protein were included in the SDS-PAGE
and Western blot analysis. Only the concentrated purified fraction (Fig. 4.4.8 (B), lane 5)
was, however, detected with immunoblotting using the His-probe, indicating a low level
of expression of the aromatase protein in the yeast. The lighter bands (Fig. 4.4.8 (B), lane
5) may be due to the degradation of the aromatase protein.
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Fig. 4.4.8. AnalysiS oftbe purification of aromatase from P.pastoris. (A) Image ofSDS-PAGE (10%)
and (B) Western blot analysiS using a His-tagged probe at 1:3000. Lane 1: Crude extract. Lane 2:
Microsomal fraction. Lane 3: Rainbow marker. Lane 4: Filtered microsomal fraction that was loaded onto
the column. Lane S: Concentrated purified fraction obtained from the !MAC purification. A clear dark
band of the expressed aromatese protein (SS kD} can be seen in (B).
4.5 Discussion
Cytochrome P450arom, a membrane bound, microsomal enzyme, displays tissue-specific
regulation. The aromatase protein is expressed in the ovaries, placenta, brain and adipose
tissue of mammals and plays a crucial role in steroidogenesis. It catalyses three sequential
oxygenation reactions that converts C19 androgens to aromatic CIS estrogens [6,S,9}.
Estrogen biosynthesis by adipose tissue increases with body weight and age, and this
possibly leads to increased incidence of both breast cancer and EC, which is believed to
develop and progress as a result of abnormal expression of aromatase [10,11,12].
The study of human cytochromes P450 is complicated by the relative low expression
levels in tissues and organs where these hemoproteins are active. Heterologous
expression of these proteins can facilitate investigations of enzyme activities and
structure/function relationships . fn addition, heterologous expression can also aid in the
evaluation of the effect of xenobiotics on these enzymes as well as provide sufficient pure
cytochrome P450 proteins for the preduetion of antibodies for immunochemical and
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immunohistochemical studies. These studies could include the localization of aromatase
in breast tissue.
P. pastoris, an eukaryotic methylotrophic yeast, was chosen as the heterologous
expression system in this study since it provides all the advantages of higher eukaryotic
expression, such as protein processing and folding, and posttranslational modification
[72-75].
The successful integration of the Cï? 19 gene into the P.pastoris genome, was achieved
by electroporation, verified with direct PCR screening of transformed cells and analysed
by agarose gel electrophoretic analysis (Fig. 4.4.2).
SDS-PAGE and Western blot analyses of the cells pellets of P. pastoris GS 115 cells
expressing aromatase, identified a protein fraction corresponding to a molecular mass of
55 kO. The concentration of this protein, according to the intensity of the
chemiluminescent signal, gradually decreased from 48 h to 72 h. A possible reason for
the relative low expression of the CYP 19 could be the retention of expressed aromatase
in the ER of the yeast cell or a low copy number integration of CYP19 into the yeast
genome. It must however, be noted that high plasmid copy number is not always a
guarantee for increased protein production in P. pastoris [74,104].
The recombinant P. pastoris cells converted androstenedione to estrone indicating a
functional expressed enzyme in P. pastoris with the endogenous yeast reductase system
capable of electron transport to the human aromatase. It is interesting to note that after 2
h the conversion of androstenedione to estrone reached equilibrium. This incomplete
conversion of substrate can be ascribed to two factors: (a) the supply of dissolved oxygen
in the small 25 ml Erlenmeyer flasks used for incubation could be insufficient to sustain a
high rate of substrate conversion or (b) the reducing equivalents available could not
support a higher substrate conversion rate. The influence of these two parameters on
substrate conversion by aromatase will be investigated in follow up studies in this
laboratory, but is beyond the scope of this investigation.
For the isolation of aromatase from P. pastoris cells, it was possible to solubilise
aromatase from the membrane fraction with the addition of Emulgen 913 to the cell
lysate. lMAC was used to successfully purify the recombinant human aromatase from P.
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pastoris. Inclusion of ~-mercaptoethanol in the solubilisation buffer prevented co-
aggregation of aromatase and endogenous yeast proteins thereby facilitating the elution of
unwanted proteins during the purification process. An intense signal was detected with
the His-tag probe at a molecular mass corresponding to 55 kD (Fig. 4.4.8 (B)). The less
intense bands at lower molecular masses could be attributed to the degradation of the
aromatase protein.
An increase in yield of aromatase can potentially be accomplished by producing multi-
copy strains with the pPIC3.5K-CYP19 by following different transformation strategies,
such as truncating the amino terminal end, although it may not produce a functional
protein.
The results obtained in this study indicate that P. pastoris is a suitable heterologous
expression system for the production of unmodified human aromatase. The enzyme was
active in vivo and could also be isolated from cell lysate using lMAC. With modifications
to the expression vector to yield a higher copy number, sufficient amounts of aromatase
protein can be produced for further enzymatic studies as well as the production of
polyclonal and monoclonal antibodies.
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CHAPTER FIVE
Cytochrome P450 17a-hydroxylase/17,20-1yase
5.1 Introduction
The cytochrome P450 17a-hydroxylase/17,20-1yase represents a major metabolic branch
point in adrenal steroidogenesis between glucocorticoid and mineralocorticoid production
as well as between glucocorticoid and androgen production [10,14,15,79]. P450c17 has
dual activity. It catalyses the hydroxylation, at C17, of the C21steroids and the C17, C20-
lyase of C17 hydroxylated steroids. The ratio of the two catalytic activities of P450c 17 is
influenced by the tissue in which it is expressed, since different tissues exhibit different
steroidogenic requirements [2,5,7,79-83]. P450c17 is expressed as a membrane bound
protein in the ER of the adrenals, ovaries and testis as well as various non-steroidal
tissues, which include the brain, liver and intestines [5,14,15,19,79,81,83]. This
hemoprotein contains two transmembrane segments at the NH2-terminus that anchor the
protein to the membrane through the formation of a hairpin loop structure. When
P450c 17 is analyzed by SDS-PAGE, it exhibits a single band corresponding to a
molecular mass of approximately 53 kO [5,14,15,19,79,81,83]. The 17a-hydroxylase
function of P450c 17 is responsible for converting pregnenolone and progesterone to
17preg and 170Hprog, respectively. The second activity of this enzyme, namely the
17,20-lyase function, cleaves 170Hpreg and 170Hprog at their steroid side chain to yield
DHEA and androstenedione respectively (Fig. 5.1.1) [2,5,7,10,14,15,19,79-83].
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Fig. 5.1.1. Reactions catalysed by P450c17. 3[3HSD; 3[3-hydroxy-il5-steroiddehydrogenase-isomerase.
5.2 The CYP17gene
The cytochrome P450 designated CYP 17 (Fig. 5.2.1) is located on chromosome IO of the
human genome. It is a single copy gene, mapped to q24.3 of chromosome 10. The gene
spans 6569 bp on the chromosome and is divided into eight exons which span 6 kb and
seven introns. The full-length cDNA of P450c 17 is 1527 bp in length and encodes for a
single 508 amino acids polypeptide protein [7,82,84,85]. Adrenocorticotropin (ACTH)
regulates the biosynthesis of all major adrenocortical hormones. This is achieved by
maintaining transcriptional pressure on the genes encoding the biosynthesis of these
hormones via the second messenger cAMP. Each gene uses its own unique cAMP
response system during this coordinate response. A number of consensus sequences are
found in the 5' flanking region of the CYP17 gene. These sequences, the cis-acting cAMP
regulatory elements (CRE) and activator protein 1 (AR-I) or activator protein 2 (AR-2)
binding sites bind cAMP to induce gene transcription. For the CYP17 gene to be
expressed, only 310 bp of the exon is required [86-88]. In the past it was thought that
families of genes or at least subfamilies are regulated in the same manner. However, this
assumption is incorrect. A combination of transcriptional activation, posttranscriptional
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and posttranslational regulation regulates the genes encoding the cytochrome P450-
dependent enzymes [7,85-88].
- .....1 ......-----4
6569 bp
Fig. 5.2.1. Schematic representation of the human CYP17 gene, indicating the approximate locations
and sizes of the 8 exons.
5.3 The mechanism of CYP17catalysis
The P450cl7 enzyme is responsible for three different reactions in humans: firstly, the
17a-hydroxylation of pregnenolone and progesterone to form 170Hpreg and 170Hprog
respectively; secondly, the 17, 20 carbon-carbon bond cleavage of 170Hpreg and
170Hprog. A third reaction, the 16a-hydroxylation of progesterone, is found only in
humans. The ratio of 160Hprog to 170Hprog for the human P450c 17 catalysed reaction
is approximately 1:4 [5,10,14,15,79-84,89-92].
The hydroxylation of progesterone at the C17 position is well documented. The activated
oxygen molecule, known as oxene, is formed by the heterolytic cleavage of the iron-
bound peroxy intermediate. A substrate-based radical and an equivalent of an iron-bound
hydroxyl radical are formed because the hydrogen atom is abstracted from the substrate
by the oxene. The recombining of these two radical species produces the hydroxylated
product [89]. Fig. 5.3.1 is a schematic representation of the 17a-hydroxylation reaction
cycle ofP450c17 [89].
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Fig. 5.3.1. Schematic representation of the 17a-hydroxylation reaction cycle catalyzed by P450c17
that occurs via oxene chemistry (891.
The P450c 17 enzyme also catalyses a carbon-carbon bond cleavage reaction, which is not
as well understood as the 17n-hydroxylation reaction. It has been reported that it is
possible that a substrate-bound ferric peroxy intermediate is involved in P450c17
oxidations [89,90]. P450c17 catalyses the formation of androstenedione from 170Hprog
via a ferric-peroxy-dependent pathway also known as a Baeyer- Villiger rearrangement.
The intermediate that is formed during this conversion could possibly rearrange
heterolytically via this Baeyer-Villiger rearrangement to form a hemiacetal or rearrange
homolytically to form the gem diol [89,90]. Fig. 5.3.2 is a schematic representation of the
peroxide chemistry reaction, catalyzed by P450c 17 [89]. The intermediates are
hydrolyzed to yield a C19 steroid. It is also possible that protons play a role in the
differentiation between oxene and peroxide chemistry. The chemistry and product
identity of the P450c17 reaction is determined by the state of protonation of the ferric
peroxide intermediate [89,90].
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Fig. 5.3.2. Schematic representation of peroxide chemistry as catalyzed by P450c17. The intermediate
could rearrange homolytically or heterolytically via the Baeyer-Villiger rearrangement (89).
In the human adrenal gland, there are four main enzymes involved in steroidogenesis. In
the mitochondria P450scc and P450c Il are found, while P450c21 and P450c 17 are located
in the ER [2,10,14,15,79]. The three different steroid hormones that are synthesized in the
adrenal glands are mineralocorticoids, glucocorticoids and androgens. The
mineralocorticoids are involved in regulating electrolyte and water balance, while the
glucocorticoids regulate carbohydrate, protein and lipid metabolism. The androgens play
an essential role in secondary sex characteristics [7,15,93].
As mentioned before, P450c 17 has dual activity and is expressed in the zonae fasiculata
and reticularis of the adrenal ER. In these two zonae, pregnenolone acts as substrate to
produce glucocorticoids. In the zona glomerulosa, the cAMP concentration is low and
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therefore no P450c17 is expressed since cAMP is crucial for inducing gene expression as
mentioned in section 5.1 [14,15,80,87,93-95]. Fig. 5.4.1 is a schematic representation of a
cross-section of the adrenal gland, showing the different zones'.
Fig. 5.4.1. Schematic representation of a cross section of the adrenal gland. It shows the different
zones ofthe gland. P450cl7 is expressed in two zones in the cortex, namely the zonae fasiculata and
reticularis.
While the theca interna cells in the ovaries express P450c17 there is very low expression
in the granulosa cells. Androgens are produced in the theca interna cells via P450cl7,
whereafter these androgen precursors can move to the granulosa cells where estrogens are
produced [80,83,95,70].
When the P450cl7 enzyme cannot catalyze the 17a-hydroxylase or 17, 20-lyase
reactions, no sex hormones are produced. This deficiency in the enzyme leads to the
production of female genitalia despite of the genetic sex. Ifonly the 17, 20-lyase activity
is lost, P450cI7 can still catalyze the hydroxylation of the CZI steroids, which means that
sufficient cortisol is still being produced. However, production of sex hormones is still
lost [10,80,83,85,96].
5 http://arbl.cvmbs.colostate.edu/hbooks/pathphys/endocrine/adrenal/histo overview.html
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5.4.1 P4S0C17 substrates
The mitochondria produce pregnenolone and this steroid subsequently moves to the ER.
In the ER, either P450c 17 or 3p-HSD can convert it to the steroid intermediates. When
P450c 17 hydroxylates pregnenolone at the C17 position, it yields 170Hpreg. The lyase
activity of P450c17 can then convert 170Hpreg to DHEA. 3p-HSD can convert
pregnenolone or 170Hpreg to yield progesterone or 170Hprog respectively, providing
substrates for P450c 17. 3p-HSD also converts DHEA to androstenedione. P450c 17
hydroxylates progesterone to form 170Hprog and the C 17-C20 carbon-carbon bond of
170Hprog is cleaved to yield androstenedione. In the human, progesterone is also 16a-
hydroxylated to yield 160Hprog [7,10,14,15,79-84,89-95,96,97].
The dual activity of P450c 17 is differentially regulated and responsible for the important
shift in steroid metabolism in different tissues. Factors that are thought to influence the
ratio of these two reactions include the electron flow to the enzyme as well as the
enzyme, cytochrome b, [19,83].
5.5 CYP17and cancer
In the 5' -untranslated region of CYP 17, a single base pair polymorphism (T to C
substitution) creates an Sp I-type (CCACC box) promoter site that is 34 bp upstream from
the initiation site of translation but 27 bp downstream from the transcription start site.
Due to this base pair change, a recognition site is created for the MspAI restriction
enzyme. Researchers have used MspAI digestion of a PCR fragment to designate two
alleles. The undigested allele is called A 1 and the digested allele A2 [84,85,92]. This
polymorphism of the CYP 17 gene has been implicated, in many studies, to be involved
with the onset of EC, breast cancer, polycystic ovarian syndrome (PCOS) and higher
levels of serum estradiol in women [63,84,85,91,92,96,97]. In men, it has been associated
with increased risk of prostate cancer, benign prostatic hyperplasia (BPH) and male-
pattern baldness [85]. However, researchers are not sure whether the CCACC site affects
endocrine status, whether the AlIA2 polymorphic site is a causative mutation or if it is
simply a marker for another mutation affecting enzymatic activity. An additional Sp-I
type promoter site in the 5' -untranslated region of CYP 17 is associated with the A2
allele. It is thought that the number of 5' promoter elements correlates with promoter
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activity. It is speculated that this CCACC site enhances CYP17 transcription that leads to
increased activity and ultimately increased serum estrogen levels [63,84,85,91,92,96,97].
As discussed in section 3.4, four steroids play an important role in tumor endocrine
response. Since progesterone and estrogen have an interrelationship, progesterone has
also been studied for its effect on breast cancer. Huggins et al. [52] have suggested that
progesterone plays an important role in tumor growth stimulation. Progesterone may
control breast tumor growth by directly affecting the tumor or by modifying actions of
other steroid hormones which influence the mammary gland. McGuire et al. [48] found
that estradiol enhances the sensitivity of the tissue to progesterone through increased
progesterone receptor levels.
The initiation or promotion of EC is associated with excess estrogen and androgen levels
as well as with hyperinsulinemia. It is possible that some allelic polymorphisms of the
genes involved in steroidogenesis contribute to EC susceptibility. Although mutations of
so-called 'normal' genetic variability are usually accompanied by visible changes, the
influence of allelic polymorphisms on the phenotype is much less distinctive
[63,91,92,96,97]. Bernstein et al. [96] found that the A2/A2 genotype of CYP17 is a risk
in breast cancer but is under-represented in EC patients. They concluded that the Al /A I
genotype, which was thought to be the normal genotype, might be one of the risk factors
for EC. In another study by Bernstein et al. [96], they compared CYP17 and CYP19
genetic polymorphisms. These studies showed that females with the highest risk of
developing EC are carriers of the Al/Al or AlIA2 genotype ofCYP17 and the A6/A6 or
A6/A7 CYPI9 genotypes. These patients also exhibited increased aromatase activity in
their tumors. Aromatase expression was only observed during EC, while no aromatase is
expressed in the normal endometrium. Bernstein et al. [96] therefore suggested that a
'high risk' CYPI9 or CYPI7 genotype might transform into a 'high activity' phenotype,
leading to increased estrogen production, hence supporting further tumor growth. Since
aromatase is responsible for estrogen production this argument seems logical for CYPI9
polymorphisms. For CYPI7 there may be two explanations. Firstly, P450c 17 catalyses
androgen biosynthesis, the precursors for estrogen production. Secondly, it may be true
Stellenbosch University http://scholar.sun.ac.za
73
that hyperinsulinemia is involved by stimulating ovarian steroidogenesis and aromatase
activity directly in endometrium cells [63].
Haiman et al. [91] found, in correspondence with the observations by Bernstein et al.
[63,96], that women carrying the A2 allele of CVP 17 are at decreased risk of developing
EC. In postmenopausal women, they did not detect a definite association between the
CYP 17 genotype and circulating steroid hormone levels. However, in premenopausal
women with the A2 allele, the CYP17 genotype and circulating steroid hormone levels
may lead to increased production of all steroid hormones because of enhanced
steroidogenesis. Although they found only modest associations between CYP 17 genotype
and hormone levels, a strong association was observed between CYP17 genotype and EC
risk. This observation might suggest that the Al or A2 alleles may be serving as markers
of a functional variant in a nearby gene. Haiman et al. [91] and Hsieh et al. [97] found
evidence that the A2 allele of CYP17 is associated with a decreased risk for developing
EC; however, the CYP17 genotype has a negligible if any effect on steroidogenesis in
post-menopausal women. In EC patients, a higher percentage of the All Al genotype is
present. There is still much controversy on whether the two alleles of CYP17 are indeed
involved in cancer risk, possibly due to multiple enzymatic processes and interactions
[91,97]. Hsieh et al. [97] suggested that this polymorphism of the CYP17 gene may be in
linkage disequilibrium with an unidentified functional polymorphism in the CYP 17 gene
which may influence EC risk.
It is controversial whether the variant allele of CYPI7 is associated with the subset of
breast cancer or PCOS. However, Miyoshi et al. [92] detected CYP17 mRNA in breast
cancer tumor tissue and found that it is significantly up regulated compared to normal
breast tissue. These researchers suggested that the CYP 17 mRNA is involved in the
initiation and development of breast cancer by increasing in situ synthesis of estrogens.
Their results showed that the CVP 17 genetic polymorphism is associated with
intratumoral estradiol levels but not with CYP17mRNA expression levels [92].
As discussed earlier in section 3.4, there is ample evidence to support the link of genetic
susceptibility to breast cancer through estradiol biosynthesis. Feigelson et al. [84]
investigated the role of the CYP17 polymorphism in breast cancer risk. They found that
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women carrying at least one A2 allele are at increased risk of advanced breast cancer.
The A I/A I genotype is associated with a later onset of menarche, suggesting that in
females the CYPI7 genotype may be a biomarker for the onset of ovulation and advanced
breast cancer risk. However, they also observed that the later onset of menarche is only
protective in women with the AIIAI genotype [84]. Since the A2 allele may be
responsible for an increased rate of transcription of CYP17 which will ultimately lead to
increased estrogen production, it is possible that the protective benefit of late menarche is
overridden by an increased lifetime exposure to estrogens. Feigelson et al. [84] concluded
that women with the A2 allele might be good candidates for early intervention or possibly
chemoprevention efforts.
Habuchi et al. [85] investigated the association between the CYPI7 polymorphism and
the risk of prostate cancer or BPH. They found that the AliA 1 genotype in men led to an
increased risk of developing prostate cancer and BPH compared to the A2/A2 genotype.
The heterozygote genotype is at moderate risk. As mentioned before, CYP 17 is involved
in the production of androgens as well as estrogens and while prostate cancers are
androgen dependent, breast cancers are estrogen dependent. Habuchi et al. [85]
concluded that the A I allele definitely has a more androgenic effect on men, while the A2
allele has an estrogenic effect on women.
5.6 Summary
P450c 17 is the product of the CYP17 gene and represents a major branch point in
steroidogenesis. The P450c 17 enzyme is responsible for 2 different reactions, a
hydroxylation reaction of pregnenolone and progesterone and a 17, 20-lyase reaction
converting 170Hpreg and 170Hprog to yield DHEA and androstenedione respectively.
P450c 17 is a membrane bound enzyme found in the ER. The 17a-hydroxylation reaction
occurs via oxene chemistry while the 17, 20-lyase reaction occurs via peroxide chemistry
(the intermediate from the lyase reaction can rearrange either heterolytically or
homolytically). P450c 17 is expressed in the gonads and the adrenal cortex. In the zonae
fasiculata and reticularis of the adrenal, pregnenolone metabolism yields glucocorticoids.
In the zona glomerulosa there is low cAMP concentration and no P450c 17 is expressed
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since cAMP is a crucial regulator for the expression of this key enzyme. CYP17 is
closely associated with the production of estrogens via CVP 19. As a result, this enzyme
has been studied extensively for its possible involvement in female cancers as well as
certain male cancers. Researchers found a single base pair polymorphism (T to C
substitution) in the 5' -untranslated region of CVP 17. This polymorphism creates a Sp-1
type (CCACC box) promoter site. This base pair also introduces a recognition site for the
MspAl restriction enzyme. The undigested allele is called Al and the digested allele A2.
Much research has been done on these two alleles of CVP 17, as they have been
implicated in many studies to be involved with the onset of EC, breast cancer, PCOS,
prostate cancer and BPH. The A2/A2 genotype is considered 'unfavorable' in breast
cancer, while the Al/Al genotype is over-represented in EC. In males, the Al/Al
genotype indicates an increased risk of developing prostate cancer and BPH.
The relatively low expression of human cytochromes P450 in tissues and organs
complicates the study of these proteins. Heterologous expression of these proteins
facilitates investigations of enzyme activities and structure/function relationships. The
Cï]' 17 gene has previously been successfully cloned and overexpressed in P. pastoris in
our laboratory [100]. In this study, we conducted kinetic studies with human CYP17 in P.
pastoris to determine the kinetic parameters of this enzyme. Although the kinetic
properties of human P450c 17 have been previously investigated in COS 1 cells [101] and
E. coli [82], this was the first time, to our knowledge, that the kinetic properties of human
P450c17 were investigated in the yeast, P. pastoris. Progesterone was used as substrate
and steroid metabolites were analysed by HPLC. Results obtained from this study are
compared to previous findings and presented in Chapter six.
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CHAPTER SIX
An investigation of the enzyme activity of human Cytochrome
P450c17 expressed in the yeast P. pastoris
6.1 Introduction
The human CYP 17 gene has been successfully expressed in E. coli [81,83,98], S.
cerevisiae [99,102], COS I cells [101,103] and HEK-293 cells [104,71] amongst others.
This gene and its product has been extensively studied and characterized in various tissue
types. The human CYP 17 gene was previously cloned into the pPIC3.5K vector and
transformed into P. pastoris OS115 cells in our laboratory [100]. In this study human
P450cl7 was expressed in P. pastoris and the catalytic activity of the expressed enzyme
investigated in vivo using progesterone as a substrate. Progesterone was chosen as
substrate as it has been previously shown that human P450c 17 has the unique ability to
convert progesterone, not only to 170Hprog, but also to 160Hprog [101]. Together with
the Km, the ratio of 17a-hydroxylase to 16a-hydroxylase activity of human P450c 17
would serve as an additional parameter to compare the enzyme activity of human
P450c 17 expressed in COS I cells and P. pastoris.
6.2 Methods
6.2.1 Activity assay of human P450c17 in P. pastoris
P. pastoris strains OSI15/pPIC3.5K-CYPI7 and OSI15/pPIC3.5K (control) were grown
as described in section 4.3.2.4. Progesterone metabolism by live yeast cells (5 x 107
cells/ml) was investigated after induction with methanol for 48 h in a total volume of 2
ml in a shaking incubator at 30·C. The cell suspension (4 ml per reaction) was harvested
by centrifugation at 2000 x g for 5 min at room temperature. The parent vector strain
(OSI15/pPIC3.5K) was included to serve as a control. The cell pellets were washed with
PBS and resuspended in fresh BMMY (1 ml) induction media. The resulting suspension
Stellenbosch University http://scholar.sun.ac.za
77
was pre-incubated for 15 min at 30°C in an Erlenmeyer flask (25 ml), where after the
reaction was initiated by adding an equal volume of the appropriate concentration of
progesterone and tritium-labeled progesterone (600,000 cpm) in BMMY media. Six
different concentrations (0.25, 0.5, 1, 2, 4 and 8 j.lM) of progesterone were used to
determine the kinetic characteristics of human P450c 17 expressed in yeast, P. pastoris.
The control strain, GS 115/pPIC3.5K was treated identically, however, only 8 j.lM
progesterone was added to this reaction mixture. The conversion of progesterone to
170Hprog and 160Hprog was monitored by removing aliquots of incubation medium, in
duplicate, at the following time intervals: 0, 5, 12, 20, 25, 30, 40, 50 and 60 min. This
conversion assay was repeated three times. Steroids in the culture media were extracted
with methylene chloride (100: 1 solvent to incubation mixture). The water phase was
aspirated and the methylene chloride was evaporated under a stream of nitrogen gas. The
dried steroids were redissolved in methanol for analysis by HPLC. The HPLC apparatus
(Thermo Separation Products, P4000) was equipped with an in-line UV-detector (Thermo
Separation Products, UV6000LP) and a radioactive detector (Radiomatic, Tampa, FL).
An isoeratic separation of the steroids was achieved on a reversed phase C 18 column
(Phenomenex) with a mobile phase consisting of a methanol and water mixture (75:25)
over a period of 35 min at a flow rate of 1 ml/min. All solvents used for the separation of
the steroids were filtered through a 0.45 urn pore size filter (Millipore) and degassed by
sonication. The substrate, progesterone, as well as the two products, 170Hprog and
160Hprog, were injected as standards to determine the elution time of these steroids in
this system. Detection and quantification of the steroids were done by radioactivity.
Product formation or substrate utilization was calculated as follows. The amount of radio-
activity (cpm) in each compound separated by HPLC, was obtained from the liquid
scintillation spectrometer. The total number of counts for all the compounds detected was
added and the percentage of each component calculated. Initial reaction rates were
determined by a least squares method. Total protein content for each incubation was
determined using the bicinchoninic acid method (BCA) (Pierce Chemicals Co.). The Km
as well as the Vo values were determined by non-linear regression using GraphPad Prism
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version 4.00 for Windows", Table 6.1 presents the Km as well as the ve obtained for
160Hprog, 170Hprog and progesterone, respectively.
6.3 Results
6.3.1 Conversion of progesterone to 160Hprog and 170Hprog by P450c17
The elution profile of a separation of steroid standards, progesterone, 170Hprog and
160Hprog is shown in Fig. 6.3.1 (A), while a typical separation of a mixture of steroids
obtained after incubation of progesterone with the P. pastoris expressing human CYP17
is given in Fig. 6.3.1 (B). The 160Hprog eluted first at approximately 6 min, 170Hprog
between 12 and 15 min and progesterone eluted after 20 min (Fig. 6.3.1A and B).
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Fig. 6.3.1. HPLC profiles of steroid standards (A) and steroid metabolites (B) formed by the
metabolism of radiolabeled progesterone by human P450c17 expressed in P. pastoris cells.
P. pastoris cells, transformed with human P450c 17, converted progesterone to 160Hprog
and 170Hprog (Fig. 6.3.1 (B». A 60 min time course study of progesterone (8 J.lM)
metabolism is given in Fig. 6.3.2. The ratio of 160Hprog:170Hprog produced was
approximately 1:5 across the range of progesterone concentrations (0.25 to 8 J.lM). When
160Hprog or 170Hprog production was used as a measure of the reaction rate, Km
values of2.89 and 3.10 J.1M,respectively, were obtained (Fig. 6.3.3 and 6.3.4, Table 7.1).
6 GraphPad Software, San Diego California USA, www.graphpad.com.
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The overall apparent Km for progesterone utilization by the human P450e17, expressed in
P. pastoris cells, was 2.54 J.1M (Fig. 6.3.5).
Fig. 6.3.2. Metabolism of progesterone (8 I'M) by human P450c17 expressed in P. paslori:J~Results
are representative of three indepmdmt experiments.
Fig. 6.3.3. Kinetics of 16a-OH-progederone metabolism by human P450c17 expressed in P. pas/oris
cells (apparent K_ = 2.89 I'M; Vo = 0.27 nmollminlmg protein). Results are representative of at least
three indepmdent experiments.
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Fig. 6.3.4. Kinetics of 170Hprog metabolism by human P450c17 expressed in P. pastoris cells
(apparent Km = 3.10 I-lM;Vo = 0.42 nmol/min/mg protein). Results are representative of at least three
independent experiments.
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Fig. 6.3.5. Kinetics of progesterone metabolism by human P450c17 expressed in P. pastoris cells
(apparent Km = 2.54 I-lM;Vo = 0.44 nmol/min/mg protein). Results are representative of at least three
independent experiments.
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Table 6.1 presents the Km as well as the Vo obtained for 160Hprog, 170Hprog and
progesterone, respectively.
Table 6.1 Summary of kinetics of progesterone metabolism by human P450cl7 expressed in P. pastoris
cells
Substrate or
roduct
160H
170H
2.54 ± 0.03
Results are the average of three experiments ±SD
P450c17 has dual activity, catalyzing both 17a-hydroxylase and 17, 20-lyase reactions.
P450c 17 is closely associated with the production of estrogens via aromatase. As a
consequence this enzyme has been studied for its possible involvement in female cancers
as well as certain male cancers. It has been implicated in the onset of EC, breast cancer,
PCOS and higher levels of serum estradiol in women [63,84,85,91,92,96,97]. In men, it
has been associated with increased risk of prostate cancer, BPH and male-pattern
baldness [85].
The human CYP 17 gene was previously cloned into the pPIC3.5K vector and
transformed into P. pastoris GS115 cells in our laboratory. P450c 17 was expressed in P.
pastoris as a functional enzyme [100]. The higher expression levels of P450c17,
compared to aromatase, can be attributed to possible multi-integration of CYP17 into the
yeast genome", The P. pastoris expression system was capable of supporting all of the
known activities of the human P450c 17 previously shown in COS 1 cells [10 1]. The
expressed P450c17 enzyme converted progesterone to 170Hprog and 160Hprog.
Maximum conversion of progesterone (~80 %) to its products was reached after 1 h. The
reaction was followed for an additional 2 h, however, 100 % conversion of progesterone
6.4 Discussion
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was not achieved. Incomplete substrate conversion can be attributed to the following: (a)
the dissolved oxygen supply was insufficient in the small 25 ml Erlenmeyer flasks used
for incubation and could not sustain a high rate of substrate conversion or (b) the
available reducing equivalents supporting substrate conversion was insufficient. The
160Hprog product, is characteristic of the human P450c 17 enzyme, with 16(1-
hydroxylation of progesterone by P450cl7 being identified only in humans [101]. The
ratio of 160Hprog to 170Hprog formed has previously been shown to be 1:4 for the
human P450c17 expressed in COS 1 cells [101]. The ratio obtained in the yeast cells was
approximately 1:5 (160Hprog: 170Hprog). The human P450c 17 enzyme expressed in
COS 1 cells apparently has a greater affinity for progesterone (- 0.77 11M) [101]
compared to the yeast cells (- 2.82 11M),while the yeast cells have a greater affinity for
progesterone compared to E. coli cells (-6.3 11M)[82]. It is possible that Km could not be
assessed accurately in P. pastoris due to the fact that oxygen and/or reducing equivalents
could have been limiting would influence the accurate assessment of vo and hence Km.
The kinetic constants for human P450c 17 expressed in COS 1 cells and P. pastoris differ
markedly under the conditions used in this study. Future experiments will focus on
P450c 17 expression in P. pastoris supplementing reducing equivalents and increasing the
oxygen supply to obtain more accurate vo values.
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Conclusion
Cytochrome P450 enzymes are a large family of heme-containing enzymes. Their
characteristic enzymatic function defines them as monooxygenases [1-3]. This group of
enzymes plays a crucial role in the detoxification of exogenous xenobiotics and is also
responsible for the endogenous metabolism of steroids, vitamins, fatty acids and
eicosanoids. Cytochrome P450-dependent enzymes are predominantly found in the ER,
however, they are also present in most other tissues. These enzymes can be divided into
two main groups, depending on their location, i.e. either microsomal or mitochondrial
[2,3]. The steroidogenic cytochrome P450-dependent enzymes are found in the adrenal
cortex, testis, ovary, placenta, adipose tissue and brain [2,4,5,7]. The precursor of all
steroids is cholesterol and for its conversion a sequence of cytochrome P450-dependent
monooxygenation reactions, together with ~-5 to ~-4 isomerization coupled to NAD-
dependent oxidation of the 3~-hydroxyl function, must take place. The first step in
steroidogenesis, conversion of cholesterol to pregnenolone, occurs in the mitochondria
and is catalysed by cytochrome P450scc• Pregnenolone then moves from the mitochondria
to the micro somes, where three microsomal cytochrome P450 enzymes are involved.
P450cl7 is responsible for the 17a-hydroxylation of pregnenolone or progesterone to
produce 170Hpreg or 170Hprog, respectively. The second reaction catalysed by
P450c 17 is a 17, 20 oxygenase dependent cleavage (lyase reaction) of either 170Hpreg
or 170Hprog to yield DHEA or androstenedione. P450c21 catalyses a 21-hydroxylation
reaction, with either progesterone or 170Hprog as substrates leading to the formation of
deoxycorticosterone or 11-deoxycortisol, respectively. Aromatase is the third microsomal
cytochrome P450 involved in steroidogenesis. Three sequential oxygenation reactions are
catalysed by this enzyme to convert C19 androgens to C 18 estrogens, i.e.
androstenedione to estrone or testosterone to estradiol [2,5,6,8,9,14,15,30]. The first two
reactions catalysed by aromatase are hydroxylations that take place on position C19 of
androgens. The third step, aromatization of the steroid A-ring, is brought about by the
oxygen activation. Aromatase is a single enzyme complex and all the mentioned
reactions of this enzyme are carried out at the same active site.
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Female mortality rates worldwide are significantly influenced by breast, endometrium
and ovarian cancers [11,39,40,45-48,53,58]. Many researchers detected aromatase
activity in breast cancer, implicating estrogens, the product of aromatase metabolism, in
playing a role in the development of breast carcinomas. In hormone-dependent cancers, a
continuous supply of estrogen is necessary for the initiation and promotion of the tumor.
The mRNA encoding for human aromatase has been localized in peripheral tissues in
previous studies [55,70]. To date aromatase protein levels in these tissues have not been
determined and there is still much debate over the exact localization of this protein in
breast tissue (stroma vs. epithelia) [69,70]. An economic and effective method for the
production of aromatase will be valuable in aiding research on the levels, mechanism of
action and activity of aromatase in breast cancer. By over expressing the human CYP 19
gene in P. pastoris, the expressed aromatase can be used to raise antibodies for
immunohistochemical studies that could ultimately lead to the determination and
localization of aromatase in normal and cancerous breast tissue via ELISA and
immunocytochemistry.
Since P450c 17 is closely associated with the production of estrogens via aromatase, it has
been extensively studied for its potential involvement in female as well as certain male
cancers. The onset of breast cancer, EC, PCOS and higher levels of serum estradiol levels
in women have been linked to P450c 17, while in men, it has been implicated in BPH,
male-pattern baldness and an increased risk of prostate cancer [63,84,85,91,92,96,97].
Unambiguously, cytochromes P450 play an essential role 10 biological processes in
humans, maintaining health and well being of the individual. Mutations or
malfunctioning of CVP genes encoding cytochromes P450, may give rise to human
diseases. We are still at the early stages of understanding the many roles of cytochromes
P450's in human homeostasis. Therefore, the challenge is to better define their role in
metabolism and to develop methods for determining their expression levels and activities
in vivo. Since aromatase and P450c17 have been linked to these above mentioned disease
states, it would be valuable to have a heterologous expression system producing these
proteins in sufficient amounts for further studies including kinetic assays, enzymology,
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immunohistochemistry and immunocytochemistry. Consequently, sufficient heterologous
expression is essential in cytochrome P450 research, since these proteins are only
expressed at low levels in tissues making them extremely difficult to study. The
heterologous expression of these proteins, allows the determination of enzyme activities
in foreign environments, as well as the determination of structure/function relationships
associated with cytochromes P450 by site-directed mutagenesis. Furthermore,
heterologous expression of human cytochromes P450 will aid in evaluation of the effects
of xenobiotics and inhibitors on these enzymes. Sufficient pure cytochrome P450 proteins
can be expressed for antibody production, to be used in the localization of aromatase in
breast tissue, for example. Nevertheless, heterologous expression can have numerous
problems since it is a complex process. Problems are not only encountered at the level of
protein stability but also at transcriptional level since the insertion of a foreign gene into
an expression vector or multi-copy integration into the genome of the host cell, does not
guarantee a high expression level [74,104].
In this study, the human CYP 19 gene, coding for aromatase, was integrated into the yeast
P. pastoris's genome. It was possible to induce the transformed P. pastoris cells with
methanol to express the aromatase enzyme. The assumption can be made that only one
copy of the CYP 19 gene was integrated, since transformed cells only exhibited resistance
against a G418 level of 0.25 mg/ml, which is indicative of single copy genome uptake.
However, possible retention of the protein in the yeasts' ER may also be a reason for the
lower expression of aromatase compared to P450c 17 in P. pastoris [100]8. Nonetheless,
the recombinant P. pastoris cells converted androstenedione to estrone indicating the
expression of a functionally active enzyme in P. pastoris. The endogenous yeast
reductase system was therefore capable of electron transport to the expressed human
aromatase. The conversion of androstenedione to estrone by aromatase reached
equilibrium after 2 h, with only 30 % of the substrate converted to product. P450c 17
converted within 80 % of the substrate, progesterone, to 170Hprog and 160Hprog. This
incomplete conversion of substrate in both cases can be ascribed to two factors; (a) the
8 Kolar, N.W. Department of Biochemistry, University of Stellenbosch, Stellenbosch Personal
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supply of dissolved oxygen in the small 25 ml Erlenmeyer incubation flasks, was
insufficient and/or (b) the reducing equivalents available were inadequate. The assay
may not be an accurate reflection of the vo value and subsequently the Km,since P450c 17
did not accomplish 100 % conversion. In future studies with these two cytochrome P450
enzymes, aromatase and P450c17, expressed in P. pastoris, the oxygen supply should be
increased and monitored while reducing equivalents are supplied. This may lead to an
increase in product being produced by aromatase and/or allow P450c 17 to achieve
maximum conversion.
It was possible to isolate and purify aromatase from the membrane fraction by IMAC.
With all the methods for expression and purification in place and the newly developed
HPLC based aromatase assay, it will be economical and efficient to produce and purify
large amounts of protein and conduct kinetic studies with aromatase. Higher expression
levels may be achieved by modifying the expression vector, pPIC3.5K-CYPI9, to yield a
higher copy number. Supplementing reducing equivalents and increasing the oxygen
supply during expression may result in more substrate being converted to product.
Different approaches such as truncating the amino terminal end of human CYP 19 or
another transformation strategy into yeast might also prove useful. Since the structure of
aromatase is not well-known and the antigenic determinant has not been determined, the
use of synthetic peptides to raise antibodies will be time-wasting and expensive. The
production of sufficient amounts of aromatase can be used for future enzymatic studies as
well as the production of polyclonal and monoclonal antibodies, allowing the
identification and localization of aromatase in breast tissue.
With the P. pastoris expression system it was possible to study the activity of the
expressed P450c17. The results obtained in this study indicate that P. pastoris is a
suitable heterologous expression system for the production of active unmodified human
aromatase and P450c 17. The success of over-expressing and producing unmodified
human steroidogenic cytochrome P450 enzymes in P. pastoris can assist in studying the
cytochrome P450 enzymes to investigate an array of parameters. Potential applications in
cytochrome P450 research can be exploited such as large-scale cytochrome P450
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production under well controlled conditions as well as enzyme/inhibitor interactions in
pharmaceutical applications. The cytochrome P450 content, endogenous bj and
cytochrome oxidase should be investigated as all these accessory proteins might impact
on this heterologously expressed steroidogenic cytochrome P450 to fully understand the
cellular environment of P. pastoris. The P. pastoris expression system is, without doubt a
viable expression system for producing unmodified human steroidogenic cytochrome
P450 enzymes and may also prove useful in the expression of other non-steroidogenic
cytochromes P450.
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